[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 6861
1. Telischak NA, Yeh BM, Joe BN, Westphalen AC, Poder L, Coakley FV: MRI of adnexal masses in pregnancy. AJR Am J Roentgenol; 2008 Aug;191(2):364-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: MRI can assist sonographic assessment of adnexal masses in pregnancy by depicting the characteristic findings of exophytic leiomyoma, red degeneration of leiomyoma, endometrioma, decidualized endometrioma, and massive ovarian edema.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2004 Jan;182(1):243-52 [14684546.001]
  • [Cites] J Ultrasound Med. 2004 Jun;23(6):805-19 [15244305.001]
  • [Cites] Radiology. 1986 Jun;159(3):717-24 [3517956.001]
  • [Cites] AJR Am J Roentgenol. 1987 May;148(5):901-5 [3554923.001]
  • [Cites] J Comput Assist Tomogr. 1993 May-Jun;17(3):477-9 [8491915.001]
  • [Cites] J Comput Assist Tomogr. 2008 Jul-Aug;32(4):555-8 [18664842.001]
  • [Cites] Radiology. 1999 Jan;210(1):209-16 [9885610.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Obstet Gynecol Clin North Am. 2005 Dec;32(4):569-93 [16310673.001]
  • [Cites] Eur Radiol. 2007 Dec;17(12):3236-46 [17882426.001]
  • [Cites] J Ultrasound Med. 1997 Jul;16(7):447-52; quiz 453-4 [9315194.001]
  • (PMID = 18647903.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001631-01A1; United States / NIBIB NIH HHS / EB / T32 EB001631; United States / NIBIB NIH HHS / EB / 1 T32 EB001631; United States / NIBIB NIH HHS / EB / T32 EB001631-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 13
  • [Other-IDs] NLM/ NIHMS125524; NLM/ PMC2716084
  •  go-up   go-down


2. Petrovic U: Role of oxidative stress in the extremely salt-tolerant yeast Hortaea werneckii. FEMS Yeast Res; 2006 Aug;6(5):816-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increasing environmental salinity was found to have no effect on its high ability to degrade hydrogen peroxide but resulted in a decrease in viability in response to externally added hydrogen peroxide, suggesting that the latter property determines the upper limit of the salt tolerance of H. werneckii.

  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879431.001).
  • [ISSN] 1567-1356
  • [Journal-full-title] FEMS yeast research
  • [ISO-abbreviation] FEMS Yeast Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride; BBX060AN9V / Hydrogen Peroxide
  •  go-up   go-down


3. Chao TJ, Chao J, Kuan LJ, Li YT, Kuo TC, Chang YC, Nieh S: Mature solid teratoma of the fallopian tube associated with uterine leiomyomas. J Chin Med Assoc; 2008 Aug;71(8):425-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube associated with uterine leiomyomas.
  • Benign solid teratomas within the fallopian tube are rare.
  • The incidence of this kind of benign solid teratoma of the fallopian tube associated with intrauterine leiomyomas is extremely low and may complicate the clinical manifestations.
  • Here, we report a 40-year-old female with periodic lower abdominal pain and hypermenorrhea who was found to have 3 nodules within the uterine myometrium and left distended fallopian tube.
  • Final pathology revealed benign solid teratoma of the fallopian tube associated with 3 intrauterine leiomyomas.
  • [MeSH-major] Fallopian Tube Neoplasms / pathology. Leiomyoma / pathology. Teratoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18772124.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Munteanu M, Petrescu F, Pleşea E, Stanciu E, Enache SD, Munteanu MC, Munteanu AC, Pîrşcoveanu M, Stoica Z, Gugilă I: [Pseudo-Meigs syndrome, a rare variant]. Chirurgia (Bucur); 2006 Mar-Apr;101(2):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Variantă rară de sindrom pseudo-Meigs.
  • The pseudo- Meigs syndrome is defined as a pelvic tumour, other than the ovarian fibroma complicated with ascites and hydrothorax that can be recovered after the tumour is surgically extirpated.
  • The uterine leiomyoma is an extremely rare cause of this syndrome, only 24 cases have been recorded so far, most of them presenting hydropic degeneration or necrosis.
  • The biologic explorations (the benign cytology in the pleural liquid and ascites, CA-125 with ten times the normal value) and the imagery completed the picture of a Meigs/ pseudo-Meigs syndrome that implied the laparotomy.
  • The H-P examination and the postoperative evolution confirmed the diagnosis.
  • We presented this case in order to emphasize both its rarity and its real positive and differential diagnosis problems.
  • [MeSH-major] Leiomyoma / diagnosis. Meigs Syndrome / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Hydrothorax / etiology. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752689.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


5. Zheng RH, Feng MX, Ge D, Hou YY: [Diagnosis and treatment of esophageal leiomyoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jan;8(1):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of esophageal leiomyoma].
  • OBJECTIVE: To summarize the experience of diagnosis and treatment of esophageal leiomyoma.
  • METHODS: Clinical data of 52 patients with esophageal leiomyoma were analyzed from 1993 to 2002.
  • RESULTS: About 54% patients in this group had difficulty of food intake.
  • The diagnostic accuracy of gastrointestinal barium meal series, computed tomography, gastric endoscope and endoscopic ultrasonography (EUS) for esophageal leiomyoma was 64% 44% 27% and 90% respectively.
  • All patients received operation, resection of esophageal leiomyoma by videothoracoscopy (VAS) and endoscope were performed in 6, 9 patients respectively.
  • The remaining 37 patients received regular open operation,in whom 32 cases received enucleation of esophageal leiomyoma, 5 cases received partial esophageal resection and esophageal-gastric anastomosis.
  • CONCLUSION: EUS is an effective method for diagnosing esophageal leiomyoma.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophageal Neoplasms / ultrasonography. Leiomyoma / surgery. Leiomyoma / ultrasonography

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148993.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


6. Kang WD, Kim SM, Kim YH, Choi HS: Three isolated, large retroperitoneal leiomyomas. Arch Gynecol Obstet; 2009 Sep;280(3):499-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three isolated, large retroperitoneal leiomyomas.
  • Leiomyomas are very rare as retroperitoneal neoplasms.
  • The pathogenesis of retroperitoneal leiomyomas remains obscure.
  • A 42-year-old multiparous woman presented with a large abdominopelvic mass.
  • At surgery, the uterus was displaced laterally to the right and the right kidney was displaced medially by three isolated large retroperitoneal masses.
  • The histopathologic findings of the resected three tumors revealed leiomyomas without evidence of malignancy and the remaining surgical specimens were normal.
  • This is the first case of three isolated large retroperitoneal leiomyomas without a uterine leiomyoma.
  • The distribution of retroperitoneal leiomyomas in our case suggests that these may be of primary multifocal origin, rather than metastatic or parasitic.
  • [MeSH-major] Leiomyoma. Retroperitoneal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184074.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


7. Moghadam R, Lathi RB, Shahmohamady B, Saberi NS, Nezhat CH, Nezhat F, Nezhat C: Predictive value of magnetic resonance imaging in differentiating between leiomyoma and adenomyosis. JSLS; 2006 Apr-Jun;10(2):216-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of magnetic resonance imaging in differentiating between leiomyoma and adenomyosis.
  • OBJECTIVE: We evaluated the role of MRI as a preoperative diagnostic tool for leiomyoma and adenomyosis.
  • RESULTS: The MRI and pathology report were the same for 136 of 144 women with leiomyoma and 12 of 31 women with adenomyosis.
  • The MRI had 94% sensitivity and 33% specificity for leiomyoma and 38% sensitivity and 91% specificity for adenomyosis.
  • Positive and negative predictive values of MRI for leiomyoma were 95% and 27% with 90% accuracy.
  • CONCLUSION: MRI has a high sensitivity and a low specificity for diagnosing leiomyoma and a high specificity and a low sensitivity for diagnosing adenomyosis.


8. Cruz Guerra NA, Fradejas Rodríguez A, del Valle Manteca A, Ursúa Sarmiento I, Tarroc Blanco A: [Bladder leiomyosarcoma: case report]. Arch Esp Urol; 2006 Mar;59(2):198-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Leiomiosarcoma vesical: aportacion de un nuevo caso.
  • OBJECTIVES: To report a new case of bladder leiomyoma in an adult.
  • METHODS: 64-year-old female patient consulting for a four-month hematuria diagnosed of a bladder intraluminal tumor on ultrasound during a routine gynecologic revision.
  • Cystoscopy confirmed the presence of the tumor.
  • RESULTS: Pathology reported a definitive diagnosis of leiomyosarcoma.
  • We comment on their main characteristics, pointing out the importance of immunohistochemical staining for the definitive histological diagnosis.
  • [MeSH-major] Leiomyosarcoma / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16649530.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Kraivichian K, Nuchprayoon S, Siriyasatien P, Saksirisamphan W, Nuchprayoon I: Resolution of eosinophilia after treatment of cutaneous gnathostomiasis. J Med Assoc Thai; 2005 Sep;88 Suppl 4:S163-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The absolute eosinophil count (AEC) was higher than 500/ul during infestation in almost all the patients, the positive rate was 89%, and significantly decreased to normal level after receiving albendazole and worm removal within 3 months in 96%.
  • [MeSH-minor] Adolescent. Adult. Animals. Female. Humans. Male. Middle Aged. Skin Diseases, Parasitic

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623022.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antinematodal Agents; F4216019LN / Albendazole
  •  go-up   go-down


10. Radziszewski W, Lai E, Lazarus Shipitofsky N, Stroh M, Dishy V, Han L, Lewis W, Johnson-Levonas AO, Lutz R, Wagner J: A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers. Am J Ther; 2010 Jan-Feb;17(1):8-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma samples were collected for determination of rolofylline, M1-trans, and M1-cis pharmacokinetic parameters.
  • The upper limit of the two-sided 90% confidence interval for the placebo-adjusted least squares mean change from baseline in QTcF interval for rolofylline was less than 5 msec at every time point.
  • Mean Cmax values of 1947.4, 739.2, and 54.8 nM were attained for rolofylline and its metabolites M1-trans and M1-cis, respectively, which were 2.2- to 3.1-fold higher than historic Cmax values seen at the anticipated clinical dose and regimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027105.001).
  • [ISSN] 1536-3686
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenosine A1 Receptor Antagonists; 0 / Aza Compounds; 0 / Diuretics; 0 / Fluoroquinolones; 0 / Quinolines; 0 / Xanthines; 7805S5HIHX / rolofylline; U188XYD42P / moxifloxacin
  •  go-up   go-down


11. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S: Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation; 2009 Aug 15;88(3):380-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: On documentation of a PCP case, we recommend PCP prophylaxis for a maximum period of 6 months (upper limit of incubation period) in all renal transplant recipients including those on regular maintenance immunosuppressive therapy.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667941.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / DNA, Fungal; 0 / Immunosuppressive Agents
  •  go-up   go-down


12. Shaiova L: The role of methadone in the treatment of moderate to severe cancer pain. Support Cancer Ther; 2005 Apr 1;2(3):176-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Traditionally, morphine has been the prototypical opioid for chronic cancer pain because there is no ceiling effect or upper limit and it is a naturally occurring pure mu-opioid agonist.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628169.001).
  • [ISSN] 1543-2912
  • [Journal-full-title] Supportive cancer therapy
  • [ISO-abbreviation] Support Cancer Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ozdol C, Gulec S, Rahimov U, Atmaca Y, Turhan S, Erol C: Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thromb Res; 2007;119(4):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIM: Recent studies have documented that elevation of C-reactive protein (CRP) levels after percutaneous coronary intervention (PCI) have been predictive of adverse outcome.
  • After coronary stenting, the rise in CRP levels was significantly higher in controls than those treated with naproxen (DeltaCRP=6.4 mg/L in the controls and 0.43 mg/L in the naproxen group, p<0.0001).
  • The incidence of any troponin I elevation or CK-MB elevation above upper limit of normal was not statistically different between groups.
  • However this improvement in CRP levels was not associated with any significant reduction in post-PCI myonecrosis.
  • [MeSH-major] Angioplasty, Balloon, Coronary. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Inflammation / prevention & control. Myocardial Infarction / physiopathology. Naproxen / therapeutic use

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • Hazardous Substances Data Bank. NAPROXEN .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157900.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Drug Combinations; 0 / Platelet Aggregation Inhibitors; 0 / Troponin I; 57Y76R9ATQ / Naproxen; 9007-41-4 / C-Reactive Protein; A74586SNO7 / clopidogrel; EC 2.7.3.2 / Creatine Kinase, MB Form; OM90ZUW7M1 / Ticlopidine; R16CO5Y76E / Aspirin
  •  go-up   go-down


14. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T: Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol; 2006 Jan 15;97(2):223-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Striated muscle safety of ezetimibe/simvastatin (Vytorin).
  • Despite the excellent benefit/risk profile of statins, their use is limited by a dose-related risk of adverse events, particularly those related to muscle toxicity.
  • This analysis compared the muscle safety profiles of ezetimibe/simvastatin and simvastatin monotherapy.
  • We reviewed muscle-related adverse event (AE) data from 17 randomized, blinded clinical trials (13 base and 4 extension studies), in which ezetimibe and simvastatin were either co-administered as separate entities or given as a combination tablet to 4,558 patients.
  • The following AE categories were summarized: incidence of musculoskeletal or connective-tissue AEs (all and drug related); discontinuations due to musculoskeletal or connective-tissue AEs (all and drug related); incidence of AEs reported under the term "myalgia" (all and drug related); discontinuation due to myalgia (all and drug related); incidence of "myopathy" (all and drug related); increases in creatine kinase to 3 to < 5, 5 to < 10, and > or = 10 times the upper limit of normal.
  • For all AE categories examined, the incidence of muscle-related clinical and laboratory AEs or discontinuations due to muscle-related AEs was no more common in patients taking ezetimibe/simvastatin than in those taking simvastatin alone.
  • Thus, the clinical trial experience with ezetimibe/simvastatin suggests that ezetimibe does not enhance or aggravate the muscle effects of simvastatin.
  • [MeSH-major] Azetidines / pharmacology. Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology. Muscle, Skeletal / drug effects. Simvastatin / pharmacology

  • MedlinePlus Health Information. consumer health - Statins.
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442367.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Azetidines; 0 / Drug Combinations; 0 / Ezetimibe, Simvastatin Drug Combination; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; AGG2FN16EV / Simvastatin
  •  go-up   go-down


15. Allewalt JP, Bateson MM, Revsbech NP, Slack K, Ward DM: Effect of temperature and light on growth of and photosynthesis by Synechococcus isolates typical of those predominating in the octopus spring microbial mat community of Yellowstone National Park. Appl Environ Microbiol; 2006 Jan;72(1):544-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the isolate with the highest temperature optimum and upper limit was capable of performing photosynthesis at a higher temperature than other isolates.

  • Hazardous Substances Data Bank. OXYGEN .
  • SILVA. SILVA LSU Database .
  • SILVA. SILVA SSU Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2000 Mar;66(3):1038-49 [10698769.001]
  • [Cites] Curr Opin Microbiol. 1998 Jun;1(3):271-7 [10066488.001]
  • [Cites] Annu Rev Microbiol. 2002;56:457-87 [12142474.001]
  • [Cites] Mol Ecol. 2003 May;12(5):1237-46 [12694287.001]
  • [Cites] Appl Environ Microbiol. 2003 May;69(5):2893-8 [12732563.001]
  • [Cites] Environ Microbiol. 2003 Aug;5(8):650-9 [12871232.001]
  • [Cites] Bacteriol Rev. 1969 Dec;33(4):476-504 [4984428.001]
  • [Cites] Arch Mikrobiol. 1971;78(1):25-41 [4999393.001]
  • [Cites] Nature. 1990 May 3;345(6270):63-5 [1691827.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Appl Environ Microbiol. 1992 Dec;58(12):3964-9 [1282313.001]
  • [Cites] Appl Environ Microbiol. 1994 May;60(5):1572-80 [8017936.001]
  • [Cites] Appl Environ Microbiol. 1996 Feb;62(2):340-6 [8593039.001]
  • [Cites] Appl Environ Microbiol. 1997 Apr;63(4):1375-81 [9097434.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):464-7 [9624000.001]
  • [Cites] Appl Environ Microbiol. 1996 Mar;62(3):1045-50 [11536748.001]
  • [Cites] Appl Environ Microbiol. 1994 Feb;60(2):697-704 [11536630.001]
  • [Cites] Microbiol Mol Biol Rev. 1998 Dec;62(4):1353-70 [9841675.001]
  • [Cites] Appl Environ Microbiol. 2000 Oct;66(10):4222-9 [11010863.001]
  • (PMID = 16391090.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY884052/ AY884053/ AY884054/ AY884055/ AY884056/ AY884057/ AY884058/ AY884059/ AY884060
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC1352173
  •  go-up   go-down


16. Fletcher HM, Wharfe G, Williams NP, Pedican M, Brooks A, Scott P, Gordon-Strachan G: Venous thromboembolism in Jamaican women: experience in a university hospital in Kingston. West Indian Med J; 2009 Jun;58(3):243-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To review cases of venous thromboembolism (VTE) at UHWI from 1999-2004, to identify methods of diagnosis, risk factors and to evaluate differences between survivors and fatalities.
  • METHODS: Patients coded with the diagnosis of thromboembolism at the University Hospital of the West Indies (UHWI) from 1999-2004 were identified.
  • The medical records were reviewed to determine the prevalence of thromboembolism and possible variables associated with this diagnosis.
  • Common associations were obesity, 53.5%; age over 50 years, 52.5%; hypertension, 44.7%; immobilisation, 36.3%; cardiac disease, 26%; diabetes, 19.4%; fibroids, 16.3%; surgery, 15.8% and cancer 14%.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043532.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


17. Lampmann LE, Lohle PN, Smeets A, Boekkooi PF, Vervest H, van Oirschot CM, Bremer RC: Pain management during uterine artery embolization for symptomatic uterine fibroids. Cardiovasc Intervent Radiol; 2007 Jul-Aug;30(4):809-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain management during uterine artery embolization for symptomatic uterine fibroids.
  • [MeSH-major] Analgesics, Opioid / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Embolization, Therapeutic / methods. Leiomyoma / therapy. Pain / drug therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Acetaminophen / administration & dosage. Analgesia, Patient-Controlled. Arteries. Cephalothin / administration & dosage. Dexamethasone / administration & dosage. Diclofenac / administration & dosage. Droperidol / administration & dosage. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Pain Measurement. Pirinitramide / administration & dosage. Suppositories. Uterus / blood supply

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • Hazardous Substances Data Bank. ACETAMINOPHEN .
  • Hazardous Substances Data Bank. CEPHALOTHIN .
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. DROPERIDOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17(3):471-80 [16567671.001]
  • [Cites] Lancet. 1999 Jun 12;353(9169):2051-8 [10376632.001]
  • [Cites] Lancet. 1995 Sep 9;346(8976):671-2 [7544859.001]
  • [Cites] Radiology. 2003 Feb;226(2):425-31 [12563136.001]
  • [Cites] Fertil Steril. 2003 Jan;79(1):107-11 [12524072.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1267-72 [11044020.001]
  • [Cites] Cardiovasc Intervent Radiol. 2006 Mar-Apr;29(2):179-87 [16447002.001]
  • [CommentOn] Cardiovasc Intervent Radiol. 2006 Mar-Apr;29(2):179-87 [16447002.001]
  • (PMID = 17533543.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Suppositories; 144O8QL0L1 / Diclofenac; 362O9ITL9D / Acetaminophen; 4RP92LYZ2F / Pirinitramide; 7S5I7G3JQL / Dexamethasone; O9U0F09D5X / Droperidol; R72LW146E6 / Cephalothin
  • [Other-IDs] NLM/ PMC2700250
  •  go-up   go-down


18. Hu Y, Zhang SH, Huang YG, Zhu H, Shuai CX: [Polymorphism of HLA-DRB1 and -DQB1 alleles among young women with cervical squamous cell carcinoma and its relation with human papillomavirus type 16 infection]. Zhonghua Yi Xue Za Zhi; 2010 Aug 17;90(31):2193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These patients were divided into two groups based on age, including 59 cases in young age group (≤ 35 yrs) and 107 cases in non-young age group.
  • In the mean time, 50 cases with uterine myoma treated by hysterectomy were selected as controls.
  • And it was significantly higher than 12.9% of non-young age group (P < 0.05).
  • The allele frequencies of HLA-DRB1*04 and -DRB1*09 were significantly higher among HPV 16 negative cervical SCC cases in young age group as compared with non-young age group (14.1%, 26.6% vs 5.9%, 10.5%) (P < 0.05).
  • The HLA-DRB1*07 allele was not detected among HPV 16 negative cervical SCC cases in young age group, But 14 cases (9.2%) were detected in non-young age group (P < 0.05). (2) The allele frequencies of HLA-DQB1*0501 at 7.4% and 6.3% respectively were detected among HPV 16 positive and negative cervical SCC cases in the young age group.
  • And they were significantly lower than 25.8% and 20.4% of non-young age group (P < 0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / virology. HLA-DQ Antigens / genetics. HLA-DR Antigens / genetics. Human papillomavirus 16 / pathogenicity. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029659.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-DQ Antigens; 0 / HLA-DQ beta-Chains; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains
  •  go-up   go-down


19. Hong R, Lim SC, Jung H: A myxoid liposarcoma arising in a leiomyoma of the uterus: a case report. Arch Gynecol Obstet; 2008 May;277(5):445-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A myxoid liposarcoma arising in a leiomyoma of the uterus: a case report.
  • BACKGROUND: A liposarcoma is the most frequent soft tissue sarcoma found in adults, however, a liposarcoma arising in uterus is extremely rare.
  • Indeed, a liposarcoma coexistent with a leiomyoma is even rarer and there is only one case has been reported in the English literature to date.
  • CASE: We describe a case of the uterine liposarcoma arising in a leiomyoma in 48-year-old woman who presented with dysmenorrhea, brownish vaginal discharge, and a rapidly enlarging lower abdominal mass.
  • The tumor emerged from the lower segment of the endometrium and filled the endometrial cavity as a polypoid lesion.
  • The authors of this study documented the adipocyte origin of the tumor with immunohistochemical and electron microscopical studies, the available literature was reviewed and the possible histogenesis was discussed.
  • CONCLUSION: We herein report a case of very rare primary liposarcoma arising in a submucosal uterine leiomyoma.
  • [MeSH-major] Leiomyoma / pathology. Liposarcoma, Myxoid / pathology. Neoplasms, Multiple Primary / pathology. Uterine Neoplasms / pathology


20. Wu HY, Yang LL, Zhou S: Impact of periodic health examination on surgical treatment for uterine fibroids in Beijing: a case-control study. BMC Health Serv Res; 2010;10:329
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of periodic health examination on surgical treatment for uterine fibroids in Beijing: a case-control study.
  • This study aimed to assess the impact of periodic health examination (PHE) at HEC on surgical treatment for uterine fibroids in Beijing residents.
  • METHODS: We identified 224 patients with a primary diagnosis of uterine fibroids who had surgical treatment at four Level-1 general hospitals in Beijing, from June 1, 2009 to October 20, 2009.
  • Controls were women who did not have surgery for uterine fibroids, matched (1:1 ratio) for age (within 2 years).
  • RESULTS: PHE at HEC within 2 years were associated with surgical treatment for uterine fibroids.
  • Odds ratios was 4.05 (95% CI, 2.61-6.29 P < 0.001), after adjustment for marital status, whether have children, annual family income, health insurance, education level and self-rated uterine fibroids-related symptom severity.
  • CONCLUSIONS: Our study showed PHE currently provided at HEC in China were associated with significantly increased use of surgical treatment for uterine fibroids in women.
  • [MeSH-major] Community Health Centers / statistics & numerical data. Diagnostic Tests, Routine / utilization. Leiomyoma / surgery. Physical Examination / utilization. Uterine Neoplasms / surgery


21. Oh C, Rengelshausen J, Mangold B, Etropolski M, Rauschkolb C, Wang SS, Upmalis D, Häufel T: A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. Int J Clin Pharmacol Ther; 2010 Oct;48(10):678-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Upper limits of the 90% confidence intervals (CIs) for the difference in mean DeltaQTcF between tapentadol IR 100 or 150 mg and placebo were < 10 ms (non-inferiority criterion) for all time points.
  • The lower limit of the 90% CI for mean DeltaQTcF between moxifloxacin and placebo exceeded 5 ms from 1 to 6 h after dosing, establishing assay sensitivity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20875374.001).
  • [ISSN] 0946-1965
  • [Journal-full-title] International journal of clinical pharmacology and therapeutics
  • [ISO-abbreviation] Int J Clin Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics; 0 / Phenols; 0 / Receptors, Opioid, mu; H8A007M585 / tapentadol
  •  go-up   go-down


22. Lakatos G, Szücs N, Kender Z, Czirják S, Rácz K: [Macroprolactinemia associated with pituitary macroadenoma: treatment with quinagolide]. Orv Hetil; 2010 Jun 27;151(26):1072-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Authors present the history of a 80-year-old man who proved to have, among other associated disorders, an intra- and parasellar pituitary tumor measuring 21x12x12 mm in size which was revealed by pituitary MRI.
  • The function of the pituitary-adrenal axis was normal, and other hormonal tests revealed low-normal serum gonadotropins and decreased testosterone level, whereas serum insulin-like growth factor I was normal.
  • During prolonged treatment, plasma prolactin returned close to the upper limit of normal (12.3 ng/ml) and 9 months after the beginning of treatment pituitary MRI showed a remarkable shrinkage of the pituitary tumor.
  • Authors propose that in this patient the pituitary tumor secreted macroprolactin, and they recommend a treatment trial with dopamine-agonist in pituitary macroadenomas associated with macroprolactinemia.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20558354.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 80Q9QWN15M / quinagolide; 9002-62-4 / Prolactin
  •  go-up   go-down


23. Stockley CJ, Reed MJ, Newby DE, Coull AJ, Clegg GR, Gray AJ: The utility of routine D-dimer measurement in syncope. Eur J Emerg Med; 2009 Oct;16(5):256-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nearly a half of all patients (n=94; 46%) had a plasma D-dimer concentration above the upper limit of normal, 10 of whom had a serious outcome or death at 1 month.
  • [MeSH-major] Fibrin Fibrinogen Degradation Products / analysis. Pulmonary Embolism / blood. Pulmonary Embolism / diagnosis. Syncope / blood

  • MedlinePlus Health Information. consumer health - Fainting.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19902561.001).
  • [ISSN] 1473-5695
  • [Journal-full-title] European journal of emergency medicine : official journal of the European Society for Emergency Medicine
  • [ISO-abbreviation] Eur J Emerg Med
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CAF/06/01
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D
  •  go-up   go-down


24. Palmer BR, Pilbrow AP, Frampton CM, Yandle TG, Skelton L, Nicholls MG, Richards AM: Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J; 2008 Oct;29(20):2489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction.
  • AIMS: Plasma aldosterone levels have been shown to be associated with adverse clinical outcomes after ST-elevation myocardial infarction (STEMI).
  • We investigated whether aldosterone levels in patients presenting with STEMI or non-STEMI, are predictive of mortality during prolonged follow-up.
  • METHODS AND RESULTS: Aldosterone levels were assayed in plasma taken from 583 patients within 24-96 h following acute myocardial infarction (MI).
  • The median plasma aldosterone level was 108 pmol/L and all values were below the upper limit of the normal range (800 pmol/L) except for five patients (0.9%).
  • Aldosterone tertile was significantly associated with increasing plasma levels of NTproBNP (N-terminal pro-B-type natriuretic peptide), BNP (B-type natriuretic peptide), epinephrine, and endothelin-1 (P <or= 0.010), but not ANP (atrial natriuretic peptide).
  • Patients in the lowest aldosterone tertile had a significantly better survival, over 5 years' follow-up, than those in the upper two tertiles (P = 0.0023).
  • Patients with above-median levels of both NTproBNP and aldosterone had significantly greater mortality than the remaining patients (above-median 39.8%, other patients >or=25.3% mortality, P >or= 0.026).
  • CONCLUSION: Plasma aldosterone levels post-MI are independent predictors of survival and hospitalization for heart failure over a 5-year-follow-up period.

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Heart J. 2008 Oct;29(20):2451-2 [18801919.001]
  • [ErratumIn] Eur Heart J. 2008 Dec;29(24):3068
  • (PMID = 18757359.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain; 4964P6T9RB / Aldosterone; 85637-73-6 / Atrial Natriuretic Factor
  •  go-up   go-down


25. Heaton MP, Keele JW, Harhay GP, Richt JA, Koohmaraie M, Wheeler TL, Shackelford SD, Casas E, King DA, Sonstegard TS, Van Tassell CP, Neibergs HL, Chase CC Jr, Kalbfleisch TS, Smith TP, Clawson ML, Laegreid WW: Prevalence of the prion protein gene E211K variant in U.S. cattle. BMC Vet Res; 2008 Jul 14;4:25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present report describes a high-throughput matrix-associated laser desorption/ionization-time-of-flight mass spectrometry assay for scoring the Prnp E211K variant and its use to determine an upper limit for the K211 allele frequency in U.S. cattle.
  • Based on these results, the upper bounds for prevalence of the E211K variant was estimated to be extremely low, less than 1 in 2000 cattle (Bayesian analysis based on 95% quantile of the posterior distribution with a uniform prior).

  • COS Scholar Universe. author profiles.
  • SciCrunch. OMIA - Online Mendelian Inheritance in Animals: Data: Gene Expression .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3065-70 [14970340.001]
  • [Cites] Mamm Genome. 2003 Nov;14(11):765-77 [14722726.001]
  • [Cites] Vet Rec. 1987 Oct 31;121(18):419-20 [3424605.001]
  • [Cites] Exp Neurol. 1989 Nov;106(2):204-6 [2572450.001]
  • [Cites] Vet Rec. 1991 Mar 2;128(9):199-203 [1823120.001]
  • [Cites] Lancet. 1996 Apr 6;347(9006):916-7 [8598749.001]
  • [Cites] Lancet. 1996 Apr 6;347(9006):921-5 [8598754.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):779-88 [8752271.001]
  • [Cites] Science. 1997 Oct 10;278(5336):245-51 [9323196.001]
  • [Cites] Nature. 1997 Oct 2;389(6650):448-50, 526 [9333232.001]
  • [Cites] Nature. 1997 Oct 2;389(6650):498-501 [9333239.001]
  • [Cites] Am J Hum Genet. 1999 Apr;64(4):1063-70 [10090891.001]
  • [Cites] J Am Vet Med Assoc. 2005 Apr 15;226(8):1311-4 [15844419.001]
  • [Cites] Hum Genet. 2005 Nov;118(2):166-74 [16187142.001]
  • [Cites] BMC Genet. 2006;7:51 [17092337.001]
  • [Cites] Emerg Infect Dis. 2006 Dec;12(12):1816-21 [17326930.001]
  • [Cites] PLoS Pathog. 2007 Mar;3(3):e31 [17352534.001]
  • [Cites] Arch Virol. 2008;153(1):69-79 [17896076.001]
  • [Cites] Emerg Infect Dis. 2008 Feb;14(2):298-300 [18258124.001]
  • [Cites] PLoS One. 2008;3(3):e1830 [18350166.001]
  • [Cites] Mamm Genome. 2001 Jan;12(1):32-7 [11178741.001]
  • [Cites] Mamm Genome. 2001 Mar;12(3):219-26 [11252171.001]
  • [Cites] Mamm Genome. 2002 Dec;13(12):704-10 [12514749.001]
  • [Cites] EMBO Rep. 2004 Jan;5(1):110-5 [14710195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15142-7 [15477588.001]
  • (PMID = 18625065.001).
  • [ISSN] 1746-6148
  • [Journal-full-title] BMC veterinary research
  • [ISO-abbreviation] BMC Vet. Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI077774; United States / NIAID NIH HHS / AI / P01 AI 77774-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / Prions
  • [Other-IDs] NLM/ PMC2478677
  •  go-up   go-down


26. Basavarajaiah S, Boraita A, Whyte G, Wilson M, Carby L, Shah A, Sharma S: Ethnic differences in left ventricular remodeling in highly-trained athletes relevance to differentiating physiologic left ventricular hypertrophy from hypertrophic cardiomyopathy. J Am Coll Cardiol; 2008 Jun 10;51(23):2256-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The upper limits of left ventricular hypertrophy (LVH) are established in white athletes and aid the differentiation of physiologic LVH from hypertrophic cardiomyopathy (HCM).


27. Kouyoumdjian JA, Stålberg EV: Concentric needle single fiber electromyography: comparative jitter on voluntary-activated and stimulated Extensor Digitorum Communis. Clin Neurophysiol; 2008 Jul;119(7):1614-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the jitter values in voluntarily activated (v-CNE) and stimulated (s-CNE) techniques for Extensor Digitorum Communis muscle using a disposable concentric needle electrode (CNE).
  • Upper limits for the 18th (v-CNE) and 27th highest (s-CNE) MCD were 38.9 and 30 micros, respectively (95% confidence limit).
  • [MeSH-major] Electromyography / instrumentation. Fingers / innervation. Muscle Fibers, Skeletal / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455474.001).
  • [ISSN] 1388-2457
  • [Journal-full-title] Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  • [ISO-abbreviation] Clin Neurophysiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Grandi C, Luchtenberg G, Sola H: [Nutrition assessment during pregnancy. A new weight chart]. Medicina (B Aires); 2007;67(6 Pt 2):677-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) to design a new reference weight gain chart to asses the nutritional status of pregnant women using the body mass index (BMI);.
  • In 326 pregnant women before 16th week gestation at enrollment during 2001-2002 at the Sarda' Maternity Hospital (Buenos Aires), weight, height, mid arm circumference and skinfold were measured and body mass index was calculated.
  • Compared with the reference curve, the new one showed concordance at the 50th percentile with the upper limit of the normal range.
  • [MeSH-major] Birth Weight / physiology. Body Mass Index. Nutrition Assessment. Nutrition Disorders / diagnosis. Nutritional Status / physiology. Prenatal Care / statistics & numerical data
  • [MeSH-minor] Adult. Argentina / epidemiology. Female. Gestational Age. Humans. Infant, Low Birth Weight. Infant, Newborn. Longitudinal Studies. Male. Obesity / epidemiology. Obstetric Labor Complications / diagnosis. Obstetric Labor Complications / epidemiology. Pregnancy. Pregnancy Complications / diagnosis. Pregnancy Trimesters. Reference Standards. Weight Gain


29. Aviel Y, Horn D, Abeles M: Memory capacity of balanced networks. Neural Comput; 2005 Mar;17(3):691-713
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using combinatorial arguments, we derive an upper limit on memory capacity.

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15802011.001).
  • [ISSN] 0899-7667
  • [Journal-full-title] Neural computation
  • [ISO-abbreviation] Neural Comput
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL: Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab; 2005 Feb;288(2):E462-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), the criteria used to diagnose the disorder remain poorly defined.
  • Intake of a high-fat meal did not significantly affect the measurements, and values were similar when measurements were made from the right and left hepatic lobes.
  • To determine the "upper limit of normal" for HTGC, the distribution of HTGC was examined in the 345 subjects from the DHS who had no identifiable risk factors for hepatic steatosis (nonobese, nondiabetic subjects with minimal alcohol consumption, normal liver function tests, and no known liver disease).
  • The 95th percentile of HTGC in these subjects was 5.56%, which corresponds to a hepatic triglyceride level of 55.6 mg/g.
  • Thus MRS provides a sensitive, quantitative, noninvasive method to measure HTGC and, when applied to a large urban US population, revealed a strikingly high prevalence of hepatic steatosis.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15339742.001).
  • [ISSN] 0193-1849
  • [Journal-full-title] American journal of physiology. Endocrinology and metabolism
  • [ISO-abbreviation] Am. J. Physiol. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / K25 HL 68736; United States / NCRR NIH HHS / RR / M01 RR 00633; United States / NHLBI NIH HHS / HL / P01 HL 2098; United States / NIDDK NIH HHS / DK / R01 DK 57558; United States / NIDDK NIH HHS / DK / T32 DK 07745
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triglycerides
  •  go-up   go-down


31. Aubert B, Karyotakis Y, Lees JP, Poireau V, Prencipe E, Prudent X, Tisserand V, Garra Tico J, Grauges E, Martinelli M, Palano A, Pappagallo M, Eigen G, Stugu B, Sun L, Battaglia M, Brown DN, Hooberman B, Kerth LT, Kolomensky YG, Lynch G, Osipenkov IL, Tackmann K, Tanabe T, Hawkes CM, Soni N, Watson AT, Koch H, Schroeder T, Asgeirsson DJ, Hearty C, Mattison TS, McKenna JA, Barrett M, Khan A, Randle-Conde A, Blinov VE, Bukin AD, Buzykaev AR, Druzhinin VP, Golubev VB, Onuchin AP, Serednyakov SI, Skovpen YI, Solodov EP, Todyshev KY, Bondioli M, Curry S, Eschrich I, Kirkby D, Lankford AJ, Lund P, Mandelkern M, Martin EC, Stoker DP, Atmacan H, Gary JW, Liu F, Long O, Vitug GM, Yasin Z, Sharma V, Campagnari C, Hong TM, Kovalskyi D, Mazur MA, Richman JD, Beck TW, Eisner AM, Heusch CA, Kroseberg J, Lockman WS, Martinez AJ, Schalk T, Schumm BA, Seiden A, Wang L, Winstrom LO, Cheng CH, Doll DA, Echenard B, Fang F, Hitlin DG, Narsky I, Ongmongkolkul P, Piatenko T, Porter FC, Andreassen R, Mancinelli G, Meadows BT, Mishra K, Sokoloff MD, Bloom PC, Ford WT, Gaz A, Hirschauer JF, Nagel M, Nauenberg U, Smith JG, Wagner SR, Ayad R, Toki WH, Wilson RJ, Feltresi E, Hauke A, Jasper H, Karbach TM, Merkel J, Petzold A, Spaan B, Wacker K, Kobel MJ, Nogowski R, Schubert KR, Schwierz R, Bernard D, Latour E, Verderi M, Clark PJ, Playfer S, Watson JE, Andreotti M, Bettoni D, Bozzi C, Calabrese R, Cecchi A, Cibinetto G, Fioravanti E, Franchini P, Luppi E, Munerato M, Negrini M, Petrella A, Piemontese L, Santoro V, Baldini-Ferroli R, Calcaterra A, de Sangro R, Finocchiaro G, Pacetti S, Patteri P, Peruzzi IM, Piccolo M, Rama M, Zallo A, Contri R, Guido E, Lo Vetere M, Monge MR, Passaggio S, Patrignani C, Robutti E, Tosi S, Chaisanguanthum KS, Morii M, Adametz A, Marks J, Schenk S, Uwer U, Bernlochner FU, Klose V, Lacker HM, Lueck T, Volk A, Bard DJ, Dauncey PD, Tibbetts M, Behera PK, Charles MJ, Mallik U, Cochran J, Crawley HB, Dong L, Eyges V, Meyer WT, Prell S, Rosenberg EI, Rubin AE, Gao YY, Gritsan AV, Guo ZJ, Arnaud N, Béquilleux J, D'Orazio A, Davier M, Derkach D, Firmino da Costa J, Grosdidier G, Le Diberder F, Lepeltier V, Lutz AM, Malaescu B, Pruvot S, Roudeau P, Schune MH, Serrano J, Sordini V, Stocchi A, Wormser G, Lange DJ, Wright DM, Bingham I, Burke JP, Chavez CA, Fry JR, Gabathuler E, Gamet R, Hutchcroft DE, Payne DJ, Touramanis C, Bevan AJ, Clarke CK, Di Lodovico F, Sacco R, Sigamani M, Cowan G, Paramesvaran S, Wren AC, Brown DN, Davis CL, Denig AG, Fritsch M, Gradl W, Hafner A, Alwyn KE, Bailey D, Barlow RJ, Jackson G, Lafferty GD, West TJ, Yi JI, Anderson J, Chen C, Jawahery A, Roberts DA, Simi G, Tuggle JM, Dallapiccola C, Salvati E, Cowan R, Dujmic D, Fisher PH, Henderson SW, Sciolla G, Spitznagel M, Yamamoto RK, Zhao M, Patel PM, Robertson SH, Schram M, Biassoni P, Lazzaro A, Lombardo V, Palombo F, Stracka S, Cremaldi L, Godang R, Kroeger R, Sonnek P, Summers DJ, Zhao HW, Simard M, Taras P, Nicholson H, De Nardo G, Lista L, Monorchio D, Onorato G, Sciacca C, Raven G, Snoek HL, Jessop CP, Knoepfel KJ, LoSecco JM, Wang WF, Corwin LA, Honscheid K, Kagan H, Kass R, Morris JP, Rahimi AM, Sekula SJ, Wong QK, Blount NL, Brau J, Frey R, Igonkina O, Kolb JA, Lu M, Rahmat R, Sinev NB, Strom D, Strube J, Torrence E, Castelli G, Gagliardi N, Margoni M, Morandin M, Posocco M, Rotondo M, Simonetto F, Stroili R, Voci C, del Amo Sanchez P, Ben-Haim E, Bonneaud GR, Briand H, Chauveau J, Hamon O, Leruste P, Marchiori G, Ocariz J, Perez A, Prendki J, Sitt S, Gladney L, Biasini M, Manoni E, Angelini C, Batignani G, Bettarini S, Calderini G, Carpinelli M, Cervelli A, Forti F, Giorgi MA, Lusiani A, Morganti M, Neri N, Paoloni E, Rizzo G, Walsh JJ, Lopes Pegna D, Lu C, Olsen J, Smith AJ, Telnov AV, Anulli F, Baracchini E, Cavoto G, Faccini R, Ferrarotto F, Ferroni F, Gaspero M, Jackson PD, Li Gioi L, Mazzoni MA, Morganti S, Piredda G, Renga F, Voena C, Ebert M, Hartmann T, Schröder H, Waldi R, Adye T, Franek B, Olaiya EO, Wilson FF, Emery S, Esteve L, Hamel de Monchenault G, Kozanecki W, Vasseur G, Yèche Ch, Zito M, Allen MT, Aston D, Bartoldus R, Benitez JF, Cenci R, Coleman JP, Convery MR, Dingfelder JC, Dorfan J, Dubois-Felsmann GP, Dunwoodie W, Field RC, Franco Sevilla M, Fulsom BG, Gabareen AM, Graham MT, Grenier P, Hast C, Innes WR, Kaminski J, Kelsey MH, Kim H, Kim P, Kocian ML, Leith DW, Li S, Lindquist B, Luitz S, Luth V, Lynch HL, MacFarlane DB, Marsiske H, Messner R, Muller DR, Neal H, Nelson S, O'Grady CP, Ofte I, Perl M, Ratcliff BN, Roodman A, Salnikov AA, Schindler RH, Schwiening J, Snyder A, Su D, Sullivan MK, Suzuki K, Swain SK, Thompson JM, Va'vra J, Wagner AP, Weaver M, West CA, Wisniewski WJ, Wittgen M, Wright DH, Wulsin HW, Yarritu AK, Young CC, Ziegler V, Chen XR, Liu H, Park W, Purohit MV, White RM, Wilson JR, Bellis M, Burchat PR, Edwards AJ, Miyashita TS, Ahmed S, Alam MS, Ernst JA, Pan B, Saeed MA, Zain SB, Soffer A, Spanier SM, Wogsland BJ, Eckmann R, Ritchie JL, Ruland AM, Schilling CJ, Schwitters RF, Wray BC, Drummond BW, Izen JM, Lou XC, Bianchi F, Gamba D, Pelliccioni M, Bomben M, Bosisio L, Cartaro C, Della Ricca G, Lanceri L, Vitale L, Azzolini V, Lopez-March N, Martinez-Vidal F, Milanes DA, Oyanguren A, Albert J, Banerjee S, Bhuyan B, Choi HH, Hamano K, King GJ, Kowalewski R, Lewczuk MJ, Nugent IM, Roney JM, Sobie RJ, Gershon TJ, Harrison PF, Ilic J, Latham TE, Mohanty GB, Puccio EM, Band HR, Chen X, Dasu S, Flood KT, Pan Y, Prepost R, Vuosalo CO, Wu SL, BABAR Collaboration: Search for invisible decays of the Upsilon(1S). Phys Rev Lett; 2009 Dec 18;103(25):251801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We set an upper limit on the branching fraction B(Upsilon(1S) --> invisible) < 3.0 x 10(-4) at the 90% confidence level.


32. Amin V, Wu L, Long T, Roberts R, McClure S, Ryken T: Therapy planning and monitoring of tissue ablation by high intensity focused ultrasound (HIFU) using imaging and simulation. Conf Proc IEEE Eng Med Biol Soc; 2008;2008:4471
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The HIFU is emerging as a non-invasive method for tumor ablation.
  • Pretreatment planning is an important step for a successful HIFU therapy outcome.
  • Recent developments in therapy planning using imaging are targeted for specific applications such as prostate cancer using 3-D ultrasound images and uterine fibroids using MRI.
  • This aids development of optimized, high-precision HIFU applications for a controlled ablation of the target tumor.
  • It also potentially reduces the overall treatment duration and exposure to non-target tissues.
  • [MeSH-minor] Computer Simulation. Diagnostic Imaging / methods. Heart Conduction System / physiopathology. Heart Conduction System / surgery. Humans. Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Medical Oncology / methods. Neoplasms / therapy. Software

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19163707.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Pisco JM, Tsuchiya M, Bilhim T, Duarte M, Santos D, Oliveira AG: Uterine artery embolization under electroacupuncture for uterine leiomyomas. J Vasc Interv Radiol; 2009 Jul;20(7):863-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine artery embolization under electroacupuncture for uterine leiomyomas.
  • PURPOSE: To evaluate whether electroacupuncture is a safe and effective alternative to pharmacologic sedation/analgesia in uterine artery embolization (UAE) for leiomyomas.
  • There were no significant differences in clinical outcomes, nor in uterine and leiomyoma volumes, at discharge and at 6 months (P > 0.99 and P= .72, respectively).
  • [MeSH-major] Electroacupuncture / methods. Leiomyoma / therapy. Pelvic Pain / prevention & control. Transcutaneous Electric Nerve Stimulation / methods. Uterine Artery Embolization / methods. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555885.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Wolańska M, Jaworski S: [Epidermal growth factor (EGF) in uterine leiomyoma during tumour growth]. Ginekol Pol; 2005 Aug;76(8):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermal growth factor (EGF) in uterine leiomyoma during tumour growth].
  • It is expected that leiomyoma-associated remodelling of extracellular matrix in the uterus may be evoked by changes in the content of some growth factors.
  • DESIGN: The amount and distribution of EGF in the normal myometrium and in the leiomyoma during various growth stages were investigated.
  • Our results showed that EGF bound to the uterus (normal and leiomyoma) components of different molecular mass.
  • It is of interest that some components of both, acidic and neutral extracts (myometrium and leiomyomas) were not able to bind exogenous 125I-labelled EGF.
  • [MeSH-major] Epidermal Growth Factor / analysis. Leiomyoma / chemistry. Myometrium / chemistry. Uterine Neoplasms / chemistry

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16363371.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


35. Lénárd ZM, McDannold NJ, Fennessy FM, Stewart EA, Jolesz FA, Hynynen K, Tempany CM: Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--imaging predictors of success. Radiology; 2008 Oct;249(1):187-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine leiomyomas: MR imaging-guided focused ultrasound surgery--imaging predictors of success.
  • PURPOSE: To retrospectively assess the magnetic resonance (MR) imaging predictors of success at reducing uterine leiomyoma volume and achieving patient symptom relief 12 months after MR imaging-guided focused ultrasound surgery.
  • MATERIALS AND METHODS: This single-center retrospective analysis of 71 symptomatic fibroids in 66 women was approved by the institutional review board and was HIPAA-compliant.
  • The volume of treated fibroid and nonperfused volume (NPV) were calculated with software, while symptom outcome was assessed with a symptom severity score (SSS).
  • Fibroids were classified as hyperintense or hypointense relative to skeletal muscle on pretreatment T2-weighted MR images.
  • RESULTS: Baseline volume of treated fibroids was 255.5 cm(3) +/- 201.7 (standard deviation), and baseline SSS was 61.5 +/- 14.9.
  • Both pretreatment fibroid signal intensity (SI) and posttreatment NPV predicted 12-month volume reduction independently: Fibroids with an NPV of at least 20% or with low SI both showed significantly larger volume reduction (17.0% +/- 13.0 and 17.2% +/- 20.1, respectively) than fibroids with an NPV less than 20% or with high SI (10.7% +/- 18.2 and no significant change, respectively).
  • Patients whose fibroids demonstrated an NPV of at least 20% also experienced a larger decrease in SSS than did patients with fibroids with an NPV less than 20% (50.1% +/- 19.8 vs 32.6% +/- 29.9).
  • CONCLUSION: Fibroids with low SI on pretreatment T2-weighted MR images were more likely to shrink than were ones with high SI.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Mar;226(3):897-905 [12616023.001]
  • [Cites] Radiology. 2002 Feb;222(2):367-74 [11818601.001]
  • [Cites] Radiology. 2004 Mar;230(3):803-9 [14990844.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jun;190(6):1697-703; discussion 1703-6 [15284774.001]
  • [Cites] J Vasc Interv Radiol. 2004 Aug;15(8):793-800 [15297582.001]
  • [Cites] Radiat Med. 1992 Nov-Dec;10(6):235-42 [1287735.001]
  • [Cites] Radiology. 1993 Dec;189(3):721-5 [8234695.001]
  • [Cites] J Obstet Gynaecol (Tokyo 1995). 1995 Apr;21(2):107-17 [8556572.001]
  • [Cites] Magn Reson Med. 1995 Dec;34(6):814-23 [8598808.001]
  • [Cites] J Acoust Soc Am. 2004 Oct;116(4 Pt 1):2451-8 [15532675.001]
  • [Cites] AJR Am J Roentgenol. 2004 Dec;183(6):1713-9 [15547216.001]
  • [Cites] Fertil Steril. 2006 Jan;85(1):22-9 [16412721.001]
  • [Cites] Radiology. 2006 Jul;240(1):263-72 [16793983.001]
  • [Cites] Obstet Gynecol. 2006 Jul;108(1):49-54 [16816055.001]
  • [Cites] Obstet Gynecol. 2006 Dec;108(6):1381-7 [17138770.001]
  • [Cites] Am J Obstet Gynecol. 2007 Feb;196(2):184.e1-6 [17306674.001]
  • [Cites] Radiology. 2007 Jun;243(3):885-93 [17446521.001]
  • [Cites] Int J Hyperthermia. 2007 Mar;23(2):173-82 [17578341.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 1):279-87 [17666601.001]
  • [Cites] Radiology. 2000 Mar;214(3):729-34 [10715038.001]
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):290-300 [11814511.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):48-54 [12861137.001]
  • (PMID = 18695211.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA067165; United States / NCRR NIH HHS / RR / P41 RR019703; United States / NCI NIH HHS / CA / P01CA067165; United States / NCRR NIH HHS / RR / U41RR019703
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2657858
  •  go-up   go-down


36. Gianaroli L, Gordts S, D'Angelo A, Magli MC, Brosens I, Cetera C, Campo R, Ferraretti AP: Effect of inner myometrium fibroid on reproductive outcome after IVF. Reprod Biomed Online; 2005 Apr;10(4):473-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of inner myometrium fibroid on reproductive outcome after IVF.
  • To evaluate the influence of inner myometrium fibroids (myomas) on the outcome of IVF cycles, a retrospective agematched controlled study was performed at SISMeR Reproductive Medicine Unit.
  • The study group included 129 IVF/intracytoplasmic sperm injection cycles in 75 patients with one or more intramural and/or submucosal fibroids, while the control group consisted of 129 cycles in 127 patients without fibroids.
  • Further research should be aimed at classifying fibroids on the basis of their location, especially when they are positioned in the junctional zone of the myometrium.
  • Whether this classification will be superior in predicting the impact of fibroids on the reproductive outcome should be elaborated in a large multicentric study.
  • [MeSH-major] Fertilization in Vitro. Leiomyoma / physiopathology. Myometrium. Pregnancy Complications, Neoplastic / physiopathology. Uterine Neoplasms / physiopathology


37. Ge BZ, Xu XB, Lin WL, Wang Y: [Observational study of ozone production efficiency at the Shangdianzi regional background station]. Huan Jing Ke Xue; 2010 Jul;31(7):1444-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The uncorrected data can be viewed as the upper limit of the real OPE.

  • MedlinePlus Health Information. consumer health - Ozone.
  • Hazardous Substances Data Bank. OZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20825008.001).
  • [ISSN] 0250-3301
  • [Journal-full-title] Huan jing ke xue= Huanjing kexue
  • [ISO-abbreviation] Huan Jing Ke Xue
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Nitrogen Oxides; 0 / Oxidants, Photochemical; 0 / Volatile Organic Compounds; 66H7ZZK23N / Ozone
  •  go-up   go-down


38. Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB, EPIC study investigators: Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood; 2010 Oct 7;116(14):2448-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prospective 1-year Evaluation of Patients' Iron Chelation with Exjade (EPIC) study enrolled a large cohort of 116 patients with aplastic anemia; the present analyses evaluated the efficacy and safety of deferasirox in this patient population.
  • Decreases occurred in chelation-naive (3229-1520 ng/mL; P < .001, last-observation-carried-forward analysis), and previously chelated (3263-2585 ng/mL; P = .21, last-observation-carried-forward analysis) patients and were reflective of dose adjustments and ongoing iron intake.
  • Baseline labile plasma iron levels were within normal range despite high serum ferritin levels.
  • Serum creatinine increases more than 33% above baseline and the upper limit of normal occurred in 29 patients (25%), but there were no progressive increases; concomitant use of cyclosporine had a significant impact on serum creatinine levels.
  • The decrease in mean alanine aminotransferase levels at 1 year correlated significantly with reduction in serum ferritin (r = 0.40, P < .001).
  • This prospective dataset confirms the efficacy and well characterizes the tolerability profile of deferasirox in a large population of patients with aplastic anemia.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20566896.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00171821
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzoates; 0 / Iron Chelating Agents; 0 / Triazoles; 9007-73-2 / Ferritins; AYI8EX34EU / Creatinine; V8G4MOF2V9 / deferasirox
  • [Investigator] Agaoglu L; Alimena G; Alonso D; Ame S; Angelucci E; Arrizabalaga B; Athanasiou-Metaxa M; Augustson B; Aydinok Y; Baba A; Baccarani M; Beck J; Beris P; Beyne-Rauzy O; Birgens H; Bordessoule D; Borgna-Pignatti C; Bosly A; Bouabdallah K; Bowden D; Bowen D; Bron D; Cappellini MD; Capra M; Cartron G; Cazzola M; Chalkias C; Chan LL; Chancharunee S; Chapman C; Charoenkwan P; Chasapopoulou E; Cheze S; Chuansumrit A; Cianciulli P; Dauriac C; Delforge M; Dölken G; Dombret H; Duyster J; Economopoulos T; Ehninger G; Elalfy M; El-Beshlawy A; Enggaard L; Fenaux P; Fillet G; Filosa A; Forni G; Galanello R; Gastl G; Gattermann N; Giraudier S; Goldfarb A; Grigg A; Guerci-Bresler A; Gumruk F; Ha SY; Haase D; Heinrich B; Hertzberg M; Ho J; Huang S; Hunault-Berger M; Inusa B; Jaulmes D; Jensen J; Kattamis A; Kilinc Y; Kim KH; Kinsey S; Kjeldsen L; Koren A; Lai ME; Lai Y; Lee KH; Lee SH; Legros L; Li C; Li CK; Li Q; Lin KH; Linkesch W; Lübbert M; Lutz D; Mohamed Thalha AJ; Mufti G; Muus P; Nobile F; Papadopoulos N; Perrotta S; Petrini M; Pfeilstöcker M; Piga A; Poole J; Pungolino E; Quarta G; Ravoet C; Remacha AF; Rose C; Roy L; Saglio G; Sanz G; Schmid M; Schmugge M; Schots H; Secchi G; Seymour JF; Shah F; Shah H; Shen Z; Slama B; Sutcharitchan P; Taher A; Tamary H; Taylor K; Tesch HJ; Thein SL; Troncy J; Vassilieff D; Villegas A; Viprakasit V; Wainwright L; Wassmann B; Wettervald M; Will A; Wörmann B; Wright J; Yeh SP; Zoumbos NC; Zweegman S
  •  go-up   go-down


39. Guevara-Franco JA, Alonso-Calleja C, Capita R: Aminopeptidase activity by spoilage bacteria and its relationship to microbial load and sensory attributes of poultry legs during aerobic cold storage. J Food Prot; 2010 Feb;73(2):322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A(390) values of 0.52 and 0.89 (corresponding to p-nitroaniline concentrations of 6.25 and 10.7 microg/ml, respectively) are proposed as the upper limits for acceptability on the basis of sensory and microbiological determinations, respectively.

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132678.001).
  • [ISSN] 0362-028X
  • [Journal-full-title] Journal of food protection
  • [ISO-abbreviation] J. Food Prot.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.11.- / Aminopeptidases
  •  go-up   go-down


40. Pyrcz TW, Wojtusiak J, Garlacz R: Diversity and distribution patterns of Pronophilina butterflies (Lepidoptera: Nymphalidae: Satyrinae) along an altitudinal transect in north-western Ecuador. Neotrop Entomol; 2009 Nov-Dec;38(6):716-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two assemblages of species were identified in the lower (below 2100 m) and upper (above 2300 m) sections of the transect by means of correspondence (CA) and cluster analysis.
  • 400-500 m below the upper limit of cloud forest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098916.001).
  • [ISSN] 1519-566X
  • [Journal-full-title] Neotropical entomology
  • [ISO-abbreviation] Neotrop. Entomol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


41. Lortat-Jacob B, Billard V, Buschke W, Servin F: Assessing the clinical or pharmaco-economical benefit of target controlled desflurane delivery in surgical patients using the Zeus anaesthesia machine. Anaesthesia; 2009 Nov;64(11):1229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug delivery was adjusted to maintain bispectral index between 40-60 units and systolic arterial pressure under 15 mmHg above its pre-induction value (upper limit) and over 90 mmHg (lower limit).

  • Hazardous Substances Data Bank. Isoflurane .
  • Hazardous Substances Data Bank. Desflurane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19825059.001).
  • [ISSN] 1365-2044
  • [Journal-full-title] Anaesthesia
  • [ISO-abbreviation] Anaesthesia
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Inhalation; CRS35BZ94Q / desflurane; CYS9AKD70P / Isoflurane
  •  go-up   go-down


42. Hiller S, Ibraghimov I, Wagner G, Orekhov VY: Coupled decomposition of four-dimensional NOESY spectra. J Am Chem Soc; 2009 Sep 16;131(36):12970-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the degree of chemical shift degeneracy increases with protein size, the use of 4D NOESY spectra is particularly important for large proteins.
  • Here we describe a processing method for a pair of sparsely sampled 4D NOESY spectra, a methyl-methyl and an amide-methyl NOESY, recorded on a perdeuterated protein with protonated isoleucine, leucine, and valine methyl groups.
  • At the same time, Co-MDD allows the use of low sparse levels of 10-15% of the full data grid for NOESY spectra.
  • For the 283-residue integral human membrane protein VDAC-1, which has a rotational correlation time of about 70 ns in detergent micelles, the two 4D Co-MDD NOESYs yielded a total of 366 NOEs, resulting in 139 unambiguous upper limit distance constraints for the structure calculation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomol NMR. 2005 Sep;33(1):1-14 [16222553.001]
  • [Cites] J Biomol NMR. 2005 May;32(1):61-70 [16041484.001]
  • [Cites] J Biomol NMR. 2006 Jan;34(1):31-40 [16505962.001]
  • [Cites] J Magn Reson. 2006 Apr;179(2):323-8 [16488634.001]
  • [Cites] J Am Chem Soc. 2006 Oct 18;128(41):13421-6 [17031954.001]
  • [Cites] Biochemistry. 2007 Jan 16;46(2):514-25 [17209561.001]
  • [Cites] J Biomol NMR. 2007 Mar;37(3):195-204 [17245527.001]
  • [Cites] J Am Chem Soc. 2007 Apr 25;129(16):5108-16 [17388596.001]
  • [Cites] J Am Chem Soc. 2007 Jun 27;129(25):7722-3 [17536800.001]
  • [Cites] J Magn Reson. 2007 Oct;188(2):344-56 [17822933.001]
  • [Cites] J Am Chem Soc. 2007 Nov 21;129(46):14126-7 [17973386.001]
  • [Cites] J Am Chem Soc. 2008 Mar 26;130(12):3927-36 [18311971.001]
  • [Cites] Science. 2008 Aug 29;321(5893):1206-10 [18755977.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15370-5 [18832158.001]
  • [Cites] J Biomol NMR. 2008 Dec;42(4):225-39 [18853260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17742-7 [18988731.001]
  • [Cites] Curr Opin Struct Biol. 2000 Oct;10(5):585-92 [11042458.001]
  • [Cites] J Am Chem Soc. 2003 May 14;125(19):5701-6 [12733908.001]
  • [Cites] J Biomol NMR. 2003 Oct;27(2):165-73 [12913413.001]
  • [Cites] J Am Chem Soc. 2003 Aug 27;125(34):10420-8 [12926967.001]
  • [Cites] J Am Chem Soc. 2003 Nov 12;125(45):13868-78 [14599227.001]
  • [Cites] J Am Chem Soc. 2003 Nov 19;125(46):13958-9 [14611222.001]
  • [Cites] J Biomol NMR. 2004 Sep;30(1):1-10 [15452430.001]
  • [Cites] Science. 1990 Jul 27;249(4967):411-4 [2377896.001]
  • [Cites] Science. 1991 Jun 7;252(5011):1390-9 [2047852.001]
  • [Cites] J Biomol NMR. 1992 Nov;2(6):661-5 [1490109.001]
  • [Cites] J Biomol NMR. 1994 Sep;4(5):673-87 [7919953.001]
  • [Cites] J Biomol NMR. 1995 Nov;6(3):277-93 [8520220.001]
  • [Cites] J Magn Reson B. 1996 Aug;112(2):200-5 [8812906.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):283-98 [9367762.001]
  • [Cites] Q Rev Biophys. 1998 May;31(2):145-237 [9794034.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4918-23 [10220394.001]
  • [Cites] J Biomol NMR. 1999 Apr;13(4):369-74 [10383198.001]
  • [Cites] J Magn Reson. 1999 Aug;139(2):232-9 [10423360.001]
  • [Cites] J Magn Reson. 2005 Mar;173(1):160-8 [15705524.001]
  • [Cites] J Am Chem Soc. 2005 Mar 2;127(8):2767-75 [15725035.001]
  • [Cites] J Magn Reson. 2006 Jan;178(1):72-6 [16188473.001]
  • (PMID = 19737017.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB002026; United States / NIGMS NIH HHS / GM / GM066360-05; United States / NIBIB NIH HHS / EB / EB002026-29; United States / NIGMS NIH HHS / GM / GM066360-01; United States / NIGMS NIH HHS / GM / GM047467-17; United States / NIGMS NIH HHS / GM / GM047467-180010; United States / NIBIB NIH HHS / EB / P41 EB002026; United States / NIGMS NIH HHS / GM / GM047467-170010; United States / NIGMS NIH HHS / GM / R01 GM075879; United States / NIGMS NIH HHS / GM / P01 GM047467-170011; United States / NIGMS NIH HHS / GM / GM047467-180011; United States / NIBIB NIH HHS / EB / P41 EB002026-29; United States / NIGMS NIH HHS / GM / GM075879-05; United States / NIGMS NIH HHS / GM / R01 GM075879-05; United States / NIGMS NIH HHS / GM / GM47467; United States / NIGMS NIH HHS / GM / GM075879; United States / NIGMS NIH HHS / GM / P01 GM047467-18; United States / NIBIB NIH HHS / EB / P41 EB002026-34; United States / NIGMS NIH HHS / GM / P01 GM047467; United States / NIGMS NIH HHS / GM / GM066360; United States / NIGMS NIH HHS / GM / P01 GM047467-180010; United States / NIGMS NIH HHS / GM / P41 GM066360-01; United States / NIGMS NIH HHS / GM / P01 GM047467-170010; United States / NIGMS NIH HHS / GM / R01 GM075879-04; United States / NIGMS NIH HHS / GM / GM075879-04; United States / NIBIB NIH HHS / EB / EB002026-34; United States / NIGMS NIH HHS / GM / GM047467-18; United States / NIGMS NIH HHS / GM / P01 GM047467-180011; United States / NIGMS NIH HHS / GM / P41 GM066360-05; United States / NIGMS NIH HHS / GM / P41 GM066360; United States / NIGMS NIH HHS / GM / GM047467-170011; United States / NIGMS NIH HHS / GM / P01 GM047467-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / VDAC1 protein, human; EC 1.6.- / Voltage-Dependent Anion Channel 1
  • [Other-IDs] NLM/ NIHMS140828; NLM/ PMC2771277
  •  go-up   go-down


43. Sakamoto H, Mutoh H, Ido K, Satoh S, Kumagai M, Hayakawa H, Tamada K, Sugano K: Intestinal metaplasia in gallbladder correlates with high amylase levels in bile in patients with a morphologically normal pancreaticobiliary duct. Hum Pathol; 2009 Dec;40(12):1762-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal metaplasia in gallbladder correlates with high amylase levels in bile in patients with a morphologically normal pancreaticobiliary duct.
  • In 196 patients with a normal pancreaticobiliary ductal arrangement who had undergone laparoscopic cholecystectomy, we performed intraoperative cholangiography and measured amylase levels in bile sampled from the gallbladder.
  • The cutoff value for high cystic amylase was defined as a biliary amylase level higher than the normal upper limit of serum amylase (215 IU/L).
  • In conclusion, intestinal metaplasia in the gallbladder is significantly correlated with high amylase levels in bile in patients with a morphologically normal pancreaticobiliary ductal arrangement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716161.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / Amylases
  •  go-up   go-down


44. Wang TY, Zhang M, Fu Y, Armstrong PW, Newby LK, Gibson CM, Moliterno DJ, Van de Werf F, White HD, Harrington RA, Roe MT: Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J; 2009 Apr;157(4):716-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography.
  • BACKGROUND: Because acute occlusion of coronary arteries supplying the inferolateral myocardium frequently eludes standard 12-lead electrocardiogram (ECG) diagnosis, these patients may present as non-ST-segment elevation acute coronary syndromes (NSTE-ACS).
  • Despite similar in-hospital treatment, patients with an occluded culprit artery had larger infarcts (median peak creatine kinase-MB 4.3 vs 2.1 x upper limit of normal, P < .0001) and higher risk-adjusted 6-month mortality (hazard ratio 1.72, 95% CI 1.07-2.79).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332201.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors
  •  go-up   go-down


45. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M: Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology; 2008 Feb;47(2):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (3) aminotransferase levels <or=2x the upper limit of normal.
  • A progressive significant reduction in liver stiffness values was observed (P < 0.0001) in the follow-up period in parallel with the reduction of aminotransferase levels (P < 0.0001).
  • [MeSH-major] Elasticity Imaging Techniques / methods. Hepatitis / diagnosis. Liver Cirrhosis / diagnosis
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Aspartate Aminotransferases / blood. Female. Humans. International Normalized Ratio. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2008 Jul;48(1):349-50; author reply 350 [18571790.001]
  • [CommentIn] Hepatology. 2009 Mar;49(3):1053-4; author reply 1054-5 [19241482.001]
  • [CommentIn] Hepatology. 2008 Dec;48(6):2089 [19003902.001]
  • [CommentIn] Hepatology. 2008 Jun;47(6):2140; author reply 2141 [18508302.001]
  • [CommentIn] Hepatology. 2008 Feb;47(2):370-2 [18220278.001]
  • (PMID = 18095306.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


46. Dukkipati R, Kalantar-Zadeh K: Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients? Nephrol News Issues; 2007 Jan;21(1):34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
  • Among the important guideline modifications are the elimination of the upper thresholds for hemoglobin (12 g/dL), transferrin saturation ratio (TSAT, v 50%) and ferritin (800 ng/ml).
  • The KDOQI anemia working group explains that the upper ferritin level of 500 ng/ml is not a stopping point for IV iron administration, but adds that decisions regarding IV iron administration should weigh erythropoietin responsiveness, hemoglobin and transferrin saturation level, and the patient's clinical status.The selected upper ferritin level of 500 ng/ml lacks adequate scientific evidence in the CKD population.
  • Given the lack of support from the literature, any attempt to contemplate an upper limit for serum ferritin would be arbitrary, and would not serve to improve the quality of treatment in the CKD population.

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17269263.001).
  • [ISSN] 0896-1263
  • [Journal-full-title] Nephrology news & issues
  • [ISO-abbreviation] Nephrol News Issues
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK61162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 9007-73-2 / Ferritins
  • [Number-of-references] 21
  •  go-up   go-down


47. Kim DY, Kim HJ, Lee CK, Suh JH, Kim DH, Cho YS, Won SY, Park BK, Park IS: Efficacy of adefovir dipivoxil in the treatment of lamivudine-resistant hepatitis B virus genotype C infection. Liver Int; 2007 Feb;27(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: ADV was administered for a median of 48 weeks (range: 24-120 weeks).
  • Within 32 weeks after stopping ADV therapy, serum HBV DNA levels increased to a median of 378.9 pg/ml in 88.9% of patients, who were treated for a median of 40 weeks.
  • Moreover, in some patients, the ALT level increased to more than five times the upper limit of normal.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241380.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; JAC85A2161 / Adenine; U6Q8Z01514 / adefovir dipivoxil
  •  go-up   go-down


48. Hsu CY, Lo JC, Chang JH, Chen CP, Yu S, Huang FY: Cesarean births in Taiwan. Int J Gynaecol Obstet; 2007 Jan;96(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the use of cesarean delivery in Taiwan by comparing local clinical indications with those in international cohorts.
  • Indications for cesarean delivery were evaluated with primary diagnosis codes and procedure codes from the NHI dataset.
  • The proportion of fetuses with malpresentation delivered by cesarean section in Taiwan was 7.9%, almost twice the upper limit expected for all pregnancies as indicated in international studies.
  • CONCLUSION: It is important to use appropriately documented data and to compare them with international data when monitoring local obstetric practices.

  • MedlinePlus Health Information. consumer health - Cesarean Section.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187798.001).
  • [ISSN] 0020-7292
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Yao Z, Krzyzanski W, Jusko WJ: Assessment of basic indirect pharmacodynamic response models with physiological limits. J Pharmacokinet Pharmacodyn; 2006 Apr;33(2):167-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of basic indirect pharmacodynamic response models with physiological limits.
  • Many physiological factors are regulated by homeostatic mechanisms to maintain normal body function.
  • Empirical lower Rl (Model I and IV) or upper Rh limits (Model II and III) were included in current basic indirect response (IDR) models to account for the additional role of physiological limits (IDRPL).
  • The simulations reveal that the expanded models exhibit most properties of basic indirect response models, such as slow response initiation, lag time between the kinetic and dynamic peaks, a large dose plateau, and shift in Tmax with dose.
  • Simulations demonstrate that addition of a parameter limit which is close to the baseline has a great influence on the overall and maximum responses and fitted model parameters.
  • Only stimulatory IDRPL Models III and IV allow resolution of all model parameters in the absence of clear indications or predetermined values of the lower or upper limits.
  • Indirect response models with physiological limits will be useful in characterizing drug responses for turnover systems which are maintained within a certain range.

  • MedlinePlus Health Information. consumer health - Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. D-Sorbitol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Math Biol. 2000 Dec;41(6):477-92 [11196581.001]
  • [Cites] J Pharm Sci. 1998 Jan;87(1):67-72 [9452970.001]
  • [Cites] Br J Clin Pharmacol. 2002 Sep;54(3):283-94 [12236849.001]
  • [Cites] Clin Pharmacol Ther. 1995 Dec;58(6):631-40 [8529328.001]
  • [Cites] Kidney Int. 1996 Jun;49(6):1760-4 [8743492.001]
  • [Cites] J Pharm Sci. 1998 Dec;87(12):1577-84 [10189270.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2002 Feb;29(1):1-24 [12194533.001]
  • [Cites] J Pharmacokinet Biopharm. 1996 Dec;24(6):611-35 [9300353.001]
  • [Cites] J Pharmacokinet Biopharm. 1999 Feb;27(1):23-43 [10533696.001]
  • [Cites] Clin Pharmacol Ther. 1994 Oct;56(4):406-19 [7955802.001]
  • [Cites] J Pharmacokinet Biopharm. 1993 Aug;21(4):457-78 [8133465.001]
  • [Cites] Pharm Res. 1994 Jun;11(6):816-23 [7937519.001]
  • [Cites] J Pharmacokinet Biopharm. 1999 Oct;27(5):467-89 [10948694.001]
  • [Cites] J Steroid Biochem. 1982 Dec;17(6):683-7 [7176658.001]
  • [Cites] Clin Pharmacokinet. 1999 Feb;36(2):145-67 [10092960.001]
  • [Cites] Pharm Res. 1997 Jul;14(7):949-52 [9244156.001]
  • (PMID = 16547797.001).
  • [ISSN] 1567-567X
  • [Journal-full-title] Journal of pharmacokinetics and pharmacodynamics
  • [ISO-abbreviation] J Pharmacokinet Pharmacodyn
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 57980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Enzyme Inhibitors; 0 / FR 146687; 0 / Indolizines; 0 / Naphthalenes; 0 / Pharmaceutical Preparations; 0T93LG5NMK / tolrestat; 506T60A25R / Sorbitol; EC 1.1.1.21 / Aldehyde Reductase
  •  go-up   go-down


50. Liu LF, Palmer AR, Wallace MN: Phase-locked responses to pure tones in the inferior colliculus. J Neurophysiol; 2006 Mar;95(3):1926-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At each stage along a pathway, there is a reduction in the upper frequency limit of the phase-locking and an increase in the steady-state latency.
  • In the guinea pig, phase-locked responses to pure tones have been described at various levels from auditory nerve to neocortex but not in the inferior colliculus (IC).
  • The upper limiting frequency of phase-locking varied greatly between units (80-1,034 Hz) and between anatomical divisions.
  • The upper limits in the three divisions were central nucleus, >1,000 Hz; dorsal cortex, 700 Hz; external nucleus, 320 Hz.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339005.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U135084112
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Aaltonen T, Adelman J, Alvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel J, Apresyan A, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Attal A, Aurisano A, Azfar F, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauer G, Beauchemin PH, Bedeschi F, Beecher D, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Calancha C, Camarda S, Campanelli M, Campbell M, Canelli F, Canepa A, Carls B, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Chung K, Chung WH, Chung YS, Chwalek T, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, d'Ascenzo N, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lorenzo G, Dell'Orso M, Deluca C, Demortier L, Deng J, Deninno M, d'Errico M, Di Canto A, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Dorigo T, Dube S, Ebina K, Elagin A, Erbacher R, Errede D, Errede S, Ershaidat N, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Frank MJ, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Garosi P, Gerberich H, Gerdes D, Gessler A, Giagu S, Giakoumopoulou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Group RC, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn SR, Halkiadakis E, Han BY, Han JY, Happacher F, Hara K, Hare D, Hare M, Harr RF, Hartz M, Hatakeyama K, Hays C, Heck M, Heinrich J, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Hughes RE, Hurwitz M, Husemann U, Hussein M, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jha MK, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Ketchum W, Keung J, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim HW, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Ko BR, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kreps M, Kroll J, Krop D, Krumnack N, Kruse M, Krutelyov V, Kuhr T, Kulkarni NP, Kurata M, Kwang S, Laasanen AT, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, LeCompte T, Lee E, Lee HS, Lee JS, Lee SW, Leone S, Lewis JD, Lin CJ, Linacre J, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu C, Liu T, Lockyer NS, Loginov A, Lovas L, Lucchesi D, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, MacQueen D, Madrak R, Maeshima K, Makhoul K, Maksimovic P, Malde S, Malik S, Manca G, Manousakis-Katsikakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin V, Martínez M, Martínez-Ballarín R, Mastrandrea P, Mathis M, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzione A, Mesropian C, Miao T, Mietlicki D, Miladinovic N, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Mondragon MN, Moon CS, Moore R, Morello MJ, Morlock J, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakamura K, Nakano I, Napier A, Nett J, Neu C, Neubauer MS, Neubauer S, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oakes L, Oh SH, Oh YD, Oksuzian I, Okusawa T, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramanov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Peiffer T, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Pianori E, Pinera L, Pitts K, Plager C, Pondrom L, Potamianos K, Poukhov O, Prokoshin F, Pronko A, Ptohos F, Pueschel E, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Renton P, Renz M, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rodriguez T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Rutherford B, Saarikko H, Safonov A, Sakumoto WK, Santi L, Sartori L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt A, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sforza F, Sfyrla A, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shiraishi S, Shochet M, Shon Y, Shreyber I, Simonenko A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soha A, Somalwar S, Sorin V, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Strycker GL, Suh JS, Sukhanov A, Suslov I, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tang J, Tecchio M, Teng PK, Thom J, Thome J, Thompson GA, Thomson E, Tipton P, Ttito-Guzmán P, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Totaro P, Trovato M, Tsai SY, Tu Y, Turini N, Ukegawa F, Uozumi S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Vidal M, Vila I, Vilar R, Vogel M, Volobouev I, Volpi G, Wagner P, Wagner RG, Wagner RL, Wagner W, Wagner-Kuhr J, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Weinelt J, Wester WC 3rd, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Wilbur S, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wolfe H, Wright T, Wu X, Würthwein F, Yagil A, Yamamoto K, Yamaoka J, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanetti A, Zeng Y, Zhang X, Zheng Y, Zucchelli S, CDF Collaboration: Search for R-parity violating decays of sneutrinos to eμ, μτ, and eτ pairs in pp collisions at square root s = 1.96 TeV. Phys Rev Lett; 2010 Nov 5;105(19):191801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the data consistent with the standard model expectations, we set upper limits on σ(pp→ν)×BR(ν→eμ,μτ,eτ) and use these results to constrain the RPV couplings as a function of the sneutrino mass.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21231160.001).
  • [ISSN] 1079-7114
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Sasaki H, Ohara N, Xu Q, Wang J, DeManno DA, Chwalisz K, Yoshida S, Maruo T: A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab; 2007 Feb;92(2):616-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.
  • CONTEXT: We previously demonstrated that asoprisnil, a selective progesterone receptor modulator, induces apoptosis of cultured uterine leiomyoma cells.
  • This study was conducted to evaluate whether asoprisnil activates TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptotic pathway in cultured uterine leiomyoma and matching myometrial cells.
  • The levels of TRAIL signaling molecules and cellular inhibitors of apoptosis protein were assessed by Western blot analysis.
  • RESULTS: TRAIL contents in untreated cultured leiomyoma cells were significantly (P < 0.01) lower compared with those in untreated cultured myometrial cells.
  • Asoprisnil treatment significantly (P < 0.05) increased TRAIL, DR4, and DR5 contents in cultured leiomyoma cells in a dose-dependent manner with a cleavage of caspase-8, -7, and -3, and decreased X-linked chromosome-linked inhibitor of apoptosis protein contents.
  • The concomitant treatment with 100 ng/ml P4 significantly (P < 0.05) reversed asoprisnil-induced increase in DR4 and cleaved poly(adenosine 5'-diphosphate-ribose) polymerase contents in cultured leiomyoma cells.
  • CONCLUSIONS: These results suggest that asoprisnil induces apoptosis of cultured leiomyoma cells by activating TRAIL-mediated apoptotic pathway and down-regulating X-linked chromosome-linked inhibitor of apoptosis protein levels in the absence of comparable effects on myometrial cells.
  • [MeSH-major] Estrenes / pharmacology. Leiomyoma / metabolism. Oximes / pharmacology. Oxytocics / pharmacology. Signal Transduction / drug effects. TNF-Related Apoptosis-Inducing Ligand / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Apoptosis / drug effects. Caspase 3 / metabolism. Caspase 7 / metabolism. Caspase 8 / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins / metabolism. Middle Aged. Myometrium / cytology. Receptors, Progesterone / metabolism. Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism. Receptors, Tumor Necrosis Factor / metabolism. Tumor Cells, Cultured. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105846.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrenes; 0 / Inhibitor of Apoptosis Proteins; 0 / Oximes; 0 / Oxytocics; 0 / Receptors, Progesterone; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human; 0 / TNFSF10 protein, human; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 72W09924WP / asoprisnil; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


53. Barr SI: Applications of Dietary Reference Intakes in dietary assessment and planning. Appl Physiol Nutr Metab; 2006 Feb;31(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Assessing individual intakes is complicated by the fact that neither the individual's usual nutrient intake nor their individual requirement is known.
  • Assessing diets of groups requires information on the group's usual nutrient intake distribution, which can be obtained by statistically adjusting 1 d intake distributions to remove within-person variability.
  • However, the prevalence of inadequacy cannot be determined for nutrients with an Adequate Intake (AI).
  • For individuals, these goals are met by planning intakes that meet the Recommended Dietary Allowance (RDA) or AI, are below the Tolerable Upper Intake Level (UL), and fall within the Acceptable Macronutrient Distribution Ranges (AMDRs).
  • For groups, planning involves estimating a "target" usual intake distribution with an acceptably low prevalence less than the EAR and greater than the UL, planning menus to achieve the target distribution, and assessing the results.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604145.001).
  • [ISSN] 1715-5312
  • [Journal-full-title] Applied physiology, nutrition, and metabolism = Physiologie appliquée, nutrition et métabolisme
  • [ISO-abbreviation] Appl Physiol Nutr Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


54. Lattimer JM, Prakash M: Ultimate energy density of observable cold baryonic matter. Phys Rev Lett; 2005 Mar 25;94(11):111101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate that the largest measured mass of a neutron star establishes an upper bound to the energy density of observable cold baryonic matter.
  • The largest observed mass sets the lowest upper limit to the density.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15903841.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Byrd C, Mowrey KA: Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin. Am J Health Syst Pharm; 2010 Dec 1;67(23):2038-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Lipid and transaminase levels after conversion from immediate-release niacin to extended-release niacin were evaluated.
  • Mean aspartate transaminase (AST) and alanine transaminase (ALT) levels and lipid values (low-density-lipoprotein [LDL] cholesterol, high-density-lipoprotein [HDL] cholesterol, and triglyceride levels) during Niaspan therapy were compared with the means of these values obtained after at least 90 days of Slo-Niacin therapy.
  • The majority of the patients had a decrease or no change in AST (72.5%) and ALT (69%) levels after at least 90 days of Slo-Niacin therapy.
  • None of the patients had transaminase levels greater than three times the upper limit of normal during Slo-Niacin therapy.
  • Differences in AST, ALT, triglyceride, and LDL cholesterol levels were not statistically significant between Niaspan and Slo-Niacin.
  • On the other hand, patients' mean HDL cholesterol level was significantly greater with Slo-Niacin therapy than with Niaspan (42 mg/dL versus 40 mg/dL, respectively; p < 0.05).
  • CONCLUSION: Formulary conversion from Niaspan to Slo-Niacin resulted in a small but significant increase in HDL cholesterol concentration and no significant change in ALT or AST level.

  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Health Syst Pharm. 2011 Jul 15;68(14):1294, 1297 [21719588.001]
  • (PMID = 21098376.001).
  • [ISSN] 1535-2900
  • [Journal-full-title] American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • [ISO-abbreviation] Am J Health Syst Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholesterol, HDL; 0 / Cholesterol, LDL; 0 / Delayed-Action Preparations; 0 / Hypolipidemic Agents; 0 / Triglycerides; 2679MF687A / Niacin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


56. Slev PR, Bunker AM, Owen WE, Roberts WL: Pediatric reference intervals for random urine calcium, phosphorus and total protein. Pediatr Nephrol; 2010 Sep;25(9):1707-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ), which allowed us to determine the central 95% reference intervals with 90% confidence intervals by non-parametric analysis partitioned by both gender and 2-year age intervals for each analyte [i.e. boys in age group 7-9 years (7-9 boys); girls in age group 7-9 years (7-9 girls), etc.].
  • Results for the upper limits of the central 95% reference interval were: for Ca/Cr, 0.27 (16,17 y.o.) to 0.46 mg/mg (7-9 y.o.) for the girls and 0.26 (16,17 y.o.) to 0.43 mg/mg (7-9 y.o.) for the boys; for P/Cr, 0.85 (16,17 y.o.) to 1.44 mg/mg (7-9 y.o.) for the girls and 0.87 (16,17 y.o.) to 1.68 mg/mg (7-9 y.o.) for the boys; for UTP/Cr, 0.30 (7-9 y.o.) to 0.34 mg/mg (10-12 y.o.) for the girls and 0.19 (16,17, y.o.) to 0.26 mg/mg (13-15 y.o.) for the boys.
  • Upper reference limits decreased with increasing age, and age was a statistically significant variable for all analytes.

  • MedlinePlus Health Information. consumer health - Urinalysis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2001 Dec;47(12):2137-45 [11719478.001]
  • [Cites] J Pediatr. 1997 Aug;131(2):252-7 [9290612.001]
  • [Cites] Pediatr Nephrol. 2001 Feb;16(2):133-9 [11261680.001]
  • [Cites] Curr Opin Pediatr. 1993 Apr;5(2):186-90 [8374638.001]
  • [Cites] Pediatrics. 2000 Jun;105(6):1242-9 [10835064.001]
  • [Cites] Pediatr Nephrol. 2007 Sep;22(9):1297-301 [17549524.001]
  • [Cites] N Engl J Med. 1975 Mar 6;292(10):497-500 [163960.001]
  • [Cites] J Adolesc Health Care. 1989 Jul;10(4):300-4 [2732110.001]
  • [Cites] Pediatr Nephrol. 1997 Apr;11(2):186-8 [9090660.001]
  • [Cites] Indian Pediatr. 2003 Sep;40(9):884-7 [14530550.001]
  • [Cites] Pediatr Nephrol. 1994 Feb;8(1):36-9 [8142222.001]
  • [Cites] Pediatr Nephrol. 2003 Feb;18(2):140-4 [12579403.001]
  • [Cites] Eur J Pediatr. 1984 Nov;143(1):25-31 [6510426.001]
  • [Cites] Int Urol Nephrol. 2007;39(3):917-22 [17043921.001]
  • [Cites] Pediatr Nephrol. 1992 Mar;6(2):149-57 [1571211.001]
  • [Cites] Ann Clin Biochem. 2006 Sep;43(Pt 5):398-401 [17022882.001]
  • [Cites] Acta Paediatr. 1995 Feb;84(2):156-9 [7756801.001]
  • [Cites] Pediatr Nephrol. 1999 Nov;13(9):894-9 [10603144.001]
  • (PMID = 20473690.001).
  • [ISSN] 1432-198X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 27YLU75U4W / Phosphorus; AYI8EX34EU / Creatinine; SY7Q814VUP / Calcium
  •  go-up   go-down


57. Park JY, Kim KA, Ryu JH, Lee GH, Jeon SH, Kim JS: Pharmacokinetics and the antiplatelet effect of a new clopidogrel formulation, clopidogrel besylate, in healthy subjects. Int J Clin Pharmacol Ther; 2010 Apr;48(4):259-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 90% confidence intervals (CIs) for the log-transformed ratios for pharmacokinetic parameters (Cmax and AUC) of SR26334 fell within the predefined pharmacokinetic equivalence range of 80 - 125%.
  • However, the upper limits of 90% CI of Cmax and AUC for clopidogrel exceeded the equivalence range.
  • The 90% CIs of DeltaEmax and DeltaAUEC of platelet aggregation inhibition fell within the equivalence range of 80 - 125%.
  • The test formulation proved pharmacokinetically non-inferior to the reference formulation.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CLOPIDOGREL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353747.001).
  • [ISSN] 0946-1965
  • [Journal-full-title] International journal of clinical pharmacology and therapeutics
  • [ISO-abbreviation] Int J Clin Pharmacol Ther
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Platelet Aggregation Inhibitors; A74586SNO7 / clopidogrel; OM90ZUW7M1 / Ticlopidine
  •  go-up   go-down


58. Dennedy MC, Smith D, O'Shea D, McKenna TJ: Investigation of patients with atypical or severe hyperandrogenaemia including androgen-secreting ovarian teratoma. Eur J Endocrinol; 2010 Feb;162(2):213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Features atypical of PCOS include the onset of symptoms outside the decade of 15-25 years, rapid progression of symptoms, the development of virilization and a serum testosterone concentration in excess of twice the upper limit of the reference range.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19906851.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens
  • [Number-of-references] 41
  •  go-up   go-down


59. Baudisch C, Assadian O, Kramer A: Concentration of the genera Aspergillus, Eurotium and Penicillium in 63-microm house dust fraction as a method to predict hidden moisture damage in homes. BMC Public Health; 2009;9:247
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Based on standardized measurement of mould spores in the 63-microm fraction of house dust yielded by carpets, the background concentrations were determined and compared to simultaneously obtained colony numbers and total spore numbers of the indoor air in 80 non-mouldy living areas during summer and winter periods.
  • Additionally, sampling with a vacuum-cleaner or manual sieve was compared to sampling with a filter holder or sieving machine, and the evaluative power of an established two-step assessment model (lower and upper limits) was compared to that of a one-step model (one limit) in order to derive concentration limits for mould load in house dust.

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Mal Respir. 2007 Feb;24(2):246-7 [17347615.001]
  • [Cites] Med Mycol. 2007 Feb;45(1):1-9 [17325938.001]
  • [Cites] Thorax. 2007 Sep;62(9):767-72 [17389753.001]
  • [Cites] Thorax. 2007 Sep;62(9):745-6 [17726167.001]
  • [Cites] Environ Health Perspect. 2008 Jan;116(1):45-50 [18197298.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Jan;48(1):21-8 [15650903.001]
  • [Cites] J Expo Anal Environ Epidemiol. 1999 Nov-Dec;9(6):560-8 [10638841.001]
  • [Cites] Cent Eur J Public Health. 2000 Feb;8(1):59-61 [10761630.001]
  • [Cites] Appl Environ Microbiol. 2002 Aug;68(8):3886-90 [12147486.001]
  • [Cites] Allergy. 2003 Jan;58(1):13-20 [12580801.001]
  • [Cites] Indoor Air. 2004 Jun;14(3):217-22 [15104790.001]
  • [Cites] J Occup Environ Med. 2004 Jun;46(6):596-601 [15213523.001]
  • [Cites] Int J Hyg Environ Health. 2004 Sep;207(4):369-78 [15471101.001]
  • [Cites] Allergy. 1978 Oct;33(5):268-72 [362974.001]
  • [Cites] Allergy. 1986 Sep;41(7):520-5 [3789333.001]
  • [Cites] Soc Appl Bacteriol Symp Ser. 1991;20:61S-73S [1887269.001]
  • [Cites] Allergy. 1994 Aug;49(7):533-9 [7825720.001]
  • [Cites] Allergy. 1994 Aug;49(7):540-7 [7825721.001]
  • [Cites] Clin Exp Allergy. 1998 Aug;28(8):956-64 [9756199.001]
  • [Cites] Environ Health Perspect. 1999 Jun;107 Suppl 3:469-72 [10423389.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Jan;48(1):3-11 [15650901.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Jan;48(1):12-20 [15650902.001]
  • [Cites] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005 Jan;48(1):29-35 [15650904.001]
  • [Cites] Environ Health Perspect. 2007 Feb;115(2):215-20 [17384767.001]
  • (PMID = 19615082.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dust; 059QF0KO0R / Water
  • [Other-IDs] NLM/ PMC2724515
  •  go-up   go-down


60. Grassin Delyle S, Abe E, Devillier P, Alvarez JC: Determination of rimonabant in human plasma and hair by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Sep 1;872(1-2):115-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calibration curves covered a range from 2.5 (lower limit of quantification) to 1000.0 ng/mL (upper limit of quantification) in plasma and from 2.5 to 1000.0 pg/mg in hair.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18707925.001).
  • [ISSN] 1570-0232
  • [Journal-full-title] Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • [ISO-abbreviation] J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cannabinoids; 0 / Piperidines; 0 / Pyrazoles; 158681-13-1 / rimonabant
  •  go-up   go-down


61. Heidegger T, Starzyk L, Villiger CR, Schumacher S, Studer R, Peter B, Nuebling M, Gerig HJ, Schnider TW: Fiberoptic intubation and laryngeal morbidity: a randomized controlled trial. Anesthesiology; 2007 Oct;107(4):585-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The incidence of vocal cord sequelae was 11 out of 130 (8.5%) in the fiberoptic group versus 12 out of 129 (9.3%) in the control group (chi-square = 0.057, df = 1, P = 0.81; upper limit of the one-sided 95% confidence interval for the difference: +5.1%).


62. Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW, Matisse Investigators: Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost; 2007 Jun;5(6):1191-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Primary outcomes were compared in subsets composed of patients weighing < or = and > 100 kg and with body mass index (BMI) < 30 and > or = 30 kg/m(2).
  • The upper limit in subject weight for recurrence was 166 kg (BMI 58), and for major bleeding 120 kg (BMI 39).
  • CONCLUSIONS: The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Obesity.
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403087.001).
  • [ISSN] 1538-7933
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Enoxaparin; 0 / Polysaccharides; 9005-49-6 / Heparin; J177FOW5JL / fondaparinux
  •  go-up   go-down


63. Kil HK, Cho JE, Kim WO, Koo BN, Han SW, Kim JY: Prepuncture ultrasound-measured distance: an accurate reflection of epidural depth in infants and small children. Reg Anesth Pain Med; 2007 Mar-Apr;32(2):102-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With reference to the measured distance, epidural puncture can be performed with minimal risk of dural puncture (upper limit of 95% CI = 1.67%).

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17350519.001).
  • [ISSN] 1098-7339
  • [Journal-full-title] Regional anesthesia and pain medicine
  • [ISO-abbreviation] Reg Anesth Pain Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bonaca MP, Wiviott SD, Sabatine MS, Buros J, Murphy SA, Scirica BM, Rifai N, Antman EM, Morrow DA: Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial). Am J Cardiol; 2007 Feb 1;99(3):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We measured the serum level of NT-pro-BNP using the Elecsys 2010 proBNP assay at baseline, 4 to 6 hours, and 12 to 24 hours in 747 patients undergoing elective or urgent PCI and enrolled in the JUMBO-TIMI 26 trial.
  • Periprocedural myocardial infarction (MI) was independently adjudicated and required a new increase in creatine kinase-MB >3 times the upper limit of normal distinct from MI as the indication for PCI.
  • Patients with procedural MI had significantly higher levels of NT-pro-BNP at 12 to 24 hours (405 vs 146 pg/ml, p <0.001).
  • In addition, the magnitude of increase in NT-pro-BNP correlated strongly with extent of myocardial injury, including in patients with evidence of injury (creatine kinase-MB 1 to 3 times upper limit of normal) not meeting criteria for MI (p = 0.001) or low-level increase in troponin T (p = 0.001).
  • In conclusion, periprocedural myocardial injury, even at low levels, during PCI is associated with increased hemodynamic stress as measured by increasing NT-pro-BNP.

  • MedlinePlus Health Information. consumer health - Angina.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261395.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


65. Magder S, Bafaqeeh F: The clinical role of central venous pressure measurements. J Intensive Care Med; 2007 Jan-Feb;22(1):44-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This value is a reasonable upper limit for algorithms for empiric fluid challenges.

  • MedlinePlus Health Information. consumer health - Critical Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17259568.001).
  • [ISSN] 0885-0666
  • [Journal-full-title] Journal of intensive care medicine
  • [ISO-abbreviation] J Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Pristovsek P, Franzoni L: Stereospecific assignments of protein NMR resonances based on the tertiary structure and 2D/3D NOE data. J Comput Chem; 2006 Apr 30;27(6):791-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The set of NOE distance restraints produced by nmr2st using the results of the SSA module was superior in generating good-quality ensembles of NMR structures (low deviations from upper limits in conjunction with low root-mean-square-deviation values) in the first round of structure calculations.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526035.001).
  • [ISSN] 0192-8651
  • [Journal-full-title] Journal of computational chemistry
  • [ISO-abbreviation] J Comput Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  •  go-up   go-down


67. Cheetham TC, Chan J, Benson V, Richmond C, Levin E, Campen D: Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Am J Manag Care; 2005 Sep;11(9):546-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary effectiveness end point was a comparison of the preconversion and postconversion low-density lipoprotein cholesterol (LDL-C) levels.
  • The percentage of patients with serum ALT levels greater than 3 times the upper limit of normal (ULN) was similar before (0.7%) and after (0.6%) conversion from simvastatin to lovastatin.
  • CONCLUSIONS: Overall, patients had an improvement in their lipid profile without evidence of hepatic or muscle enzyme elevations.

  • Genetic Alliance. consumer health - Hypercholesterolemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • Hazardous Substances Data Bank. LOVASTATIN .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16159044.001).
  • [ISSN] 1088-0224
  • [Journal-full-title] The American journal of managed care
  • [ISO-abbreviation] Am J Manag Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticholesteremic Agents; 0 / Drugs, Generic; 9LHU78OQFD / Lovastatin; AGG2FN16EV / Simvastatin
  •  go-up   go-down


68. Terada T: Benign Tumors of the Esophagus: A Histopathologic Study of 49 Cases among 931 Consecutive Esophageal Biopsies. Gastroenterology Res; 2009 Apr;2(2):100-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign Tumors of the Esophagus: A Histopathologic Study of 49 Cases among 931 Consecutive Esophageal Biopsies.
  • : The author reviewed 931 consecutive esophageal biopsies in the last 15 year in out pathology laboratory of our hospital in search for benign esophageal tumors.
  • As the results, 41 cases (4.4%) of squamous papilloma, 4 cases (0.4%) of granular cell tumor, 3 cases (0.3%) of leiomyoima, and 1 case (0.1%) tubular adenoma were identified.
  • It was endoscopically recognized as small polypoid tumor.
  • The 4 cases of granular cell tumor were located in the proximal esophagus in 3 cases, and in the middle esophagus in 1 case.
  • The granular cell tumor was immunohistochemically positive for vimentin, S100 protein, and neuron-specific enolase.
  • The 3 cases of leiomyoma were located in the cervical esophagus in 1 case and in the proximal esophagus in 2 cases.
  • It was immunohistochemically positive for vimentin, α-smooth muscle actin, and desmin.
  • It was endoscopically recognized as a submucosal tumor.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27956961.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Benign tumor / Clinicopathology / Esophagus / Immunohistochemistry
  •  go-up   go-down


69. Masselli G, Polettini E, Casciani E, Bertini L, Vecchioli A, Gualdi G: Small-bowel neoplasms: prospective evaluation of MR enteroclysis. Radiology; 2009 Jun;251(3):743-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred fifty patients (83 male, 67 female; mean age, 42.6 years; age range, 17-84 years) who were clinically suspected of having small-bowel neoplasm and whose previous upper and lower gastrointestinal endoscopy findings were normal underwent MR enteroclysis.
  • RESULTS: MR enteroclysis was successfully completed in all 150 patients and enabled correct detection of 19 small-bowel neoplasms, which were confirmed at histopathologic examination: three carcinoid neoplasms, two adenocarcinomas, two stromal tumors, five lymphomas, one angiomatous mass, three small-bowel metastases, one leiomyoma, one adenoma, and one lipoma.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Intestine, Small. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304922.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


70. Yamaguchi U, Hasegawa T, Sakurai S, Sakuma Y, Takazawa Y, Hishima T, Mitsuhashi T, Sekine S, Chuman H, Shimoda T: Interobserver variability in histologic recognition, interpretation of KIT immunostaining, and determining MIB-1 labeling indices in gastrointestinal stromal tumors and other spindle cell tumors of the gastrointestinal tract. Appl Immunohistochem Mol Morphol; 2006 Mar;14(1):46-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors studied the concordance among seven pathologists for the histologic diagnosis, interpretation of KIT immunostaining, and determining MIB-1 labeling indices (LI) in 80 adult patients with primary spindle cell tumors, mainly of the gastrointestinal tract, mesentery, retroperitoneum, and pelvis, based on the review of tissue sections using an immunohistochemical panel of antibodies for KIT/CD117, CD34, desmin, smooth muscle actin (SMA), and S-100 protein.
  • Tumors included 30 gastrointestinal stromal tumors (GISTs), 10 leiomyomas, 10 leiomyosarcomas, 10 schwannomas, 10 solitary fibrous tumors, and 10 desmoid-type fibromatoses.
  • The overall concordance with the original diagnosis of each histologic type was 97.9%, the kappa value ranging from 0.95 to 1.00 (mean 0.97), indicating a perfect agreement.

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16540730.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


71. Bhattarai MD: Prospects of jugular venous pulse assessment. JNMA J Nepal Med Assoc; 2010 Jul-Sep;49(179):247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However there are limitations of clinical assessment of central venous pressure by jugular vein pressure measurement from the level of sternal angle.
  • There are variations in the reported distances from sternal angle to right atrium as well as to upper limit of JVP.
  • In erect position, anterior end of fourth intercostal space is at about the level of mid-right atrium.
  • Subsequently in reclining position, the vertical height of venous pressure can be measured from the horizontal plane of the midpoint marked at lateral chest wall to visible upper limit of JVP.
  • Such measurement can be done in a more reliable way with venous pressure (VP) manometer with its indicator rod at the horizontal plane of mid-right atrium and with its horizontal surface at upper limit of JVP.
  • The venous pressure manometer can also be used to measure relatively less reliable upper limb venous pressure (ULVP), as indicated by the vertical distance at which veins of upper limb collapse, especially when JVP is not visualized due to subnormal CVP as in hypovolemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22049834.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Nepal
  •  go-up   go-down


72. Beraneck M, Uno A, Vassias I, Idoux E, De Waele C, Vidal PP, Vibert N: Evidence against a role of gap junctions in vestibular compensation. Neurosci Lett; 2009 Jan 30;450(2):97-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vestibular compensation following unilateral labyrinthectomy is associated with modifications of the membrane and firing properties of central vestibular neurons.
  • In non-lesioned animals, strong staining was observed with anti-connexin 43 antibodies, while moderate staining was obtained with the anti-connexin 36 antibody.
  • However, the expression of either type of connexin was not modified following unilateral labyrinthectomy.
  • In non-lesioned animals, the gap junction blocker carbenoxolone reversibly decreased or suppressed the spontaneous discharge of about 60% of MVN neurons.
  • Both effects were mimicked by several other gap junction blockers, but not by glycyrrhizic acid, an analog of carbenoxolone that does not block gap junctions but reproduces its non-specific effects, nor by the selective inhibitor of astrocytic connexin-based networks endothelin-1.
  • However, unilateral labyrinthectomy does not affect the expression of gap junctions in vestibular nuclei nor their implication in the regulation of neuronal activity.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19084577.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Anti-Ulcer Agents; 0 / Connexin 43; 0 / Microtubule-Associated Proteins; 0 / Mtap2 protein, rat; MM6384NG73 / Carbenoxolone; P540XA09DR / Glycyrrhetinic Acid
  •  go-up   go-down


73. Shimizu S, Tanaka R, Oka H, Fujii K: Risk of damage to the endolymphatic sac and duct during removal of the posterior meatal wall: an anatomic study. Neurosurgery; 2006 Oct;59(4 Suppl 2):ONS435-9; discussion ONS439-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distances measured were between the posterior meatal lip and the upper limit of the endolymphatic ledge, at the upper extent of the endolymphatic sac, and between a reference line extending from the inferior margin of the internal acoustic meatus posteriorly (parallel to the petrous ridge), simulating the inferior margin of the drilling, and the upper limit of the endolymphatic ledge.
  • The upper limit of the endolymphatic ledge was present on or above the reference line in approximately half of the specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041514.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Ajayi EO: Cephalometric norms of Nigerian children. Am J Orthod Dentofacial Orthop; 2005 Nov;128(5):653-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean values and standard deviations obtained for the measured variables were: SNA, 85.5 degrees (+/- 4.3 degrees); SNB, 81.2 degrees (+/- 4.0 degrees); ANB, 4.3 degrees (+/- 2.5 degrees); UI-FP, 122.8 degrees (+/- 7.5 degrees); Ll-MP, 98.8 degrees (+/- 5.8 degrees); Ul-LI, 109.1 degrees (+/- 8.0 degrees); and FMA, 26.1 degrees (+/- 5.0 degrees).
  • The findings emphasize the need for group-specific norms for orthodontic diagnosis and treatment planning, and provide cephalometric standards for Igbo children.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286214.001).
  • [ISSN] 0889-5406
  • [Journal-full-title] American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
  • [ISO-abbreviation] Am J Orthod Dentofacial Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Papakonstantinou KC, Terzis JK, Kamin E, Luka J: Early effect of gene therapy on a direct muscle neurotization model. J Reconstr Microsurg; 2005 Aug;21(6):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early effect of gene therapy on a direct muscle neurotization model.
  • Direct nerve-to-muscle neurotization has been the subject of both clinical and experimental studies.
  • In this study, the authors report a new animal model to test the regenerative properties of a nerve (musculocutaneous) implanted in a muscle (biceps).
  • They also report the early effects of the application at the implantation site of exogenously administered Brain Derived Nerve Factor (BDNF) and of endogenously produced BDNF, via the administration of an adenoviral construct with a tissue-specific promotor for muscle cells (AdRSV), and containing the BDNF gene.
  • Evaluation included behavioral testing (grooming test), electrical stimulation, Western blot analysis of the distal implanted nerve to determine the presence of locally produced BDNF, and motor end-plate staining of the biceps muscle.
  • At the early time point of 1 week following the musculocutaneous nerve to biceps muscle implantation, there was no increased production of recombinant BDNF at the distal implanted musculocutaneous nerve, as assessed by Western blot analysis.
  • In this direct nerve to muscle neurotization model, the application of AdRSV-BDNF at 3 x 10 (9) pfu/ul did not show enhanced production of BDNF at 1 week.
  • [MeSH-minor] Adenoviridae. Animals. Genetic Vectors. Male. Models, Animal. Muscle, Skeletal. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096949.001).
  • [ISSN] 0743-684X
  • [Journal-full-title] Journal of reconstructive microsurgery
  • [ISO-abbreviation] J Reconstr Microsurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Growth Substances
  •  go-up   go-down


76. Washington B, Hines B, Stoneburg S: Bladder calculi presenting as complete procidentia. Int Urogynecol J Pelvic Floor Dysfunct; 2008 Jan;19(1):157-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple large bladder stones resulting in complete procidentia present unique operative challenges.
  • A computed tomography scan of the pelvis reported a staghorn calculus in the right renal pelvis and a large calcified fibroid uterus which had prolapsed completely out of the pelvis.
  • After resolution of her urosepsis, the patient was taken to the operating room for a vaginal hysterectomy and surgical correction of her prolapse.
  • A small uterus weighing 67 g was identified with a large bladder mass.
  • Cystolithiasis should be considered when evaluating patients with large calcified prolapse.
  • [MeSH-major] Cystocele / etiology. Urinary Bladder Calculi / complications. Urinary Bladder Calculi / diagnosis. Uterine Prolapse / etiology

  • MedlinePlus Health Information. consumer health - Pelvic Support Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2003 Sep;189(3):884-5 [14526336.001]
  • [Cites] J Urol. 1998 Mar;159(3):983 [9474200.001]
  • (PMID = 17786372.001).
  • [Journal-full-title] International urogynecology journal and pelvic floor dysfunction
  • [ISO-abbreviation] Int Urogynecol J Pelvic Floor Dysfunct
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Kulishova TV, Tabashnikova NA, Akker LV: [Efficacy of general magnetotherapy in conservative therapy of uterine myoma in women of reproductive age]. Vopr Kurortol Fizioter Lech Fiz Kult; 2005 Jan-Feb;(1):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of general magnetotherapy in conservative therapy of uterine myoma in women of reproductive age].
  • Sixty women of the reproductive age with uterine myoma were divided into two groups.
  • Ultrasound investigation registered a reduction in the size of myoma nodes by 16.7% in the study group, while in the controls myoma size did not change (p < 0.05).
  • 1-year follow-up data for the study group demonstrated no cases of the myoma growth while 16.6% of the controls showed growth of myoma nodes, in 6.6% of them supravaginal myoma amputation was made for rapidly growing myoma.
  • [MeSH-major] Leiomyoma / therapy. Magnetics / therapeutic use. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15759473.001).
  • [ISSN] 0042-8787
  • [Journal-full-title] Voprosy kurortologii, fizioterapii, i lechebnoĭ fizicheskoĭ kultury
  • [ISO-abbreviation] Vopr Kurortol Fizioter Lech Fiz Kult
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


78. Vasconcelos C, Cunha TM, Félix A: Lipoleiomyoma of the peritoneum. Acta Radiol; 2007 Feb;48(1):10-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipoleiomyomas are rare, mixed mesenchymal tumors composed of adipose and smooth muscle cells.
  • They usually arise from the uterus, with extrauterine tumors being extremely rare.
  • Recognition of this rare and benign tumor is of great importance, in order to avoid erroneous diagnosis.
  • The extrauterine location was highlighted by multiplanar MRI, and the presence of a capsule suggested a benign tumor.
  • [MeSH-major] Leiomyoma / diagnosis. Lipoma / diagnosis. Magnetic Resonance Imaging / methods. Peritoneal Neoplasms / diagnosis. Peritoneum / pathology
  • [MeSH-minor] Contrast Media / administration & dosage. Diagnosis, Differential. Female. Gadolinium. Humans. Image Enhancement / methods. Middle Aged. Rare Diseases. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325918.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


79. Gaym A, Tilahun S: Torsion of pedunculated subserous myoma--a rare cause of acute abdomen. Ethiop Med J; 2007 Apr;45(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Torsion of pedunculated subserous myoma--a rare cause of acute abdomen.
  • Leiomyoma uteri are common benign genital neoplasia among women of late reproductive age.
  • Among those having symptoms, abnormal uterine bleeding and pelvic pressure symptoms are common presenting features.
  • When present, pain is usually related to complications involving the myoma including red degeneration, infection, process of expulsion of a submucous pedunculated myoma, uterine torsion, compression of myoma between the uterus and sacrum or torsion of a pedunculated subserous myoma.
  • Standard gynecologic textbooks frequently mention torsion of pedunculated subserous myoma as one of the causes of myoma related acute abdomen.
  • Literature search on the topic however does not yield many specific case reports of this myoma related complication or it's presenting features.
  • A case of torsion of pedunculated subserous myoma presenting in early pregnancy that was managed in one of the maternity hospitals in Addis Ababa, Ethiopia is presented.
  • [MeSH-major] Leiomyoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Abdomen, Acute / diagnosis. Abdomen, Acute / surgery. Adult. Diagnosis, Differential. Female. Humans. Torsion Abnormality

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642178.001).
  • [ISSN] 0014-1755
  • [Journal-full-title] Ethiopian medical journal
  • [ISO-abbreviation] Ethiop. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ethiopia
  •  go-up   go-down


80. Paul PG, Naik S: Disseminated leiomyomatosis peritonei. Incidental finding in laparoscopy: a case report. Surg Laparosc Endosc Percutan Tech; 2010 Jun;20(3):e123-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Disseminated leiomyomatosis peritonei is a rare condition characterized by multiple smooth muscle, myofibroblastic, and fibroblastic nodules.
  • We describe a 33-year-old woman with disseminated leiomyomatosis peritonei and recurrent multiple uterine leiomyomas who underwent laparoscopic myomectomy.
  • [MeSH-major] Incidental Findings. Laparoscopy. Leiomyomatosis / diagnosis. Leiomyomatosis / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551791.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Roberts A: Magnetic resonance-guided focused ultrasound for uterine fibroids. Semin Intervent Radiol; 2008 Dec;25(4):394-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance-guided focused ultrasound for uterine fibroids.
  • Uterine fibroids are an important problem for women of reproductive age.
  • Although hysterectomy has been the traditional treatment for fibroids, many women are interested in a less invasive therapy.
  • Food & Drug Administration (FDA) for the treatment of uterine fibroids.
  • Techniques of treatment of uterine fibroids are still being refined, but significant progress has been made in understanding some of the challenges for this new technology.
  • Some fibroids are more responsive to the focused ultrasound; some fibroids are more resistant.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 2002 Feb;99(2):290-300 [11814511.001]
  • [Cites] Radiat Med. 2008 May;26(4):198-205 [18509719.001]
  • [Cites] Hum Reprod. 2006 May;21(5):1255-9 [16410334.001]
  • [Cites] Am J Obstet Gynecol. 2006 Oct;195(4):955-64 [16723104.001]
  • [Cites] Radiology. 2006 Jul;240(1):263-72 [16793983.001]
  • [Cites] Curr Opin Obstet Gynecol. 2006 Aug;18(4):402-6 [16794420.001]
  • [Cites] Obstet Gynecol. 2006 Jul;108(1):49-54 [16816055.001]
  • [Cites] Mayo Clin Proc. 2006 Jul;81(7):936-42 [16835973.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):163-7 [17030549.001]
  • [Cites] J Perinatol. 2007 Jan;27(1):59-61 [17180132.001]
  • [Cites] Radiology. 2007 Jun;243(3):885-93 [17446521.001]
  • [Cites] Eur Radiol. 2007 Oct;17(10):2505-11 [17473924.001]
  • [Cites] J Vasc Interv Radiol. 2007 May;18(5):681-5 [17494853.001]
  • [Cites] Int J Gynaecol Obstet. 2007 Oct;99(1):56-7 [17599842.001]
  • [Cites] Expert Rev Med Devices. 2007 Jul;4(4):539-47 [17605689.001]
  • [Cites] Fertil Steril. 2007 Aug;88(2):255-71 [17658523.001]
  • [Cites] J Minim Invasive Gynecol. 2007 Sep-Oct;14(5):616-21 [17848324.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Oct;30(5):771-7 [17899577.001]
  • [Cites] J Obstet Gynaecol Res. 2007 Dec;33(6):834-9 [18001451.001]
  • [Cites] Radiographics. 2007 Nov-Dec;27(6):1819-26 [18025520.001]
  • [Cites] Obstet Gynecol. 2007 Dec;110(6):1427-8; author reply 1428-9 [18055746.001]
  • [Cites] Obstet Gynecol. 2008 Jan;111(1):22-33 [18165389.001]
  • [Cites] Clin Obstet Gynecol. 2008 Mar;51(1):159-66 [18303510.001]
  • [Cites] Obstet Gynecol. 2008 Mar;111(3):775; author reply 775-6 [18310384.001]
  • [Cites] Radiology. 2004 Mar;230(3):803-9 [14990844.001]
  • (PMID = 21326581.001).
  • [ISSN] 0739-9529
  • [Journal-full-title] Seminars in interventional radiology
  • [ISO-abbreviation] Semin Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3036536
  • [Keywords] NOTNLM ; Focused ultrasound / MR-guided / ablation / fibroids / magnetic resonance imaging / uterine leiomyoma
  •  go-up   go-down


82. Smart OC, Hindley JT, Regan L, Gedroyc WG: Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol; 2006 Jul;108(1):49-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata.
  • OBJECTIVE: Magnetic-resonance-guided focused ultrasound is a novel, noninvasive technique of thermoablation for uterine leiomyomata.
  • The hypothesis of this study was that pretreatment of leiomyomata with gonadotrophin-releasing hormone (GnRH) agonists would allow effective treatment of larger uterine leiomyomata, increasing the number of women who could benefit from this technique.
  • METHODS: We report a prospective study of women with leiomyomata in excess of 10 cm in diameter who received GnRH agonist before magnetic-resonance-guided focused ultrasound treatment.
  • Entry criteria were a minimal leiomyoma symptom severity score and confirmation of uterine dimensions based on screening magnetic resonance imaging.
  • The primary outcome measurement was reported change in symptom severity score as judged by the Uterine Fibroid Symptom and Quality of Life questionnaire.
  • A secondary outcome was the measured change in target leiomyoma volume.
  • There was an average reduction in target leiomyoma volume of 21% overall at 6 months (P < .001) and 37% at 12 months (P < .001).
  • LEVEL OF EVIDENCE: II-3.
  • [MeSH-major] Fertility Agents, Female / therapeutic use. Gonadotropin-Releasing Hormone / therapeutic use. Leiomyomatosis / therapy. Ultrasonic Therapy. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16816055.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fertility Agents, Female; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


83. Schaudien D, Müller JM, Baumgärtner W: Omental leiomyoma in a male adult horse. Vet Pathol; 2007 Sep;44(5):722-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Omental leiomyoma in a male adult horse.
  • The tumor consisted of multiple white-to-yellow lobules and displayed a firm consistency.
  • The majority of tumor cells revealed a positive immunoreaction for alpha-smooth muscle actin, vimentin, and neuron-specific enolase and were negative for S-100, factor VIII-related antigen, and glial fibrillary acidic protein.
  • Few tumor cells showed expression of desmin and c-kit.
  • On the basis of macroscopy, histology, and immunohistochemistry, an omental leiomyoma was diagnosed.
  • [MeSH-major] Horse Diseases / pathology. Leiomyoma / veterinary. Omentum / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846251.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Huang YW, Hu CY, Chen CL, Liao YT, Liu CJ, Lai MY, Chen PJ, Yang SS, Hu JT, Chen DS, Kao JH: Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. J Med Virol; 2009 Apr;81(4):588-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty carriers of hepatitis B virus (group I) with alanine aminotransferase <2x upper limit of normal (mean follow-up 83.6 months) were compared with 154 chronic hepatitis B patients (group II) with alanine aminotransferase >/=2x upper limit of normal (mean follow-up 81.3 months).

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19235869.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains
  •  go-up   go-down


85. Cavers S, Degen B, Caron H, Lemes MR, Margis R, Salgueiro F, Lowe AJ: Optimal sampling strategy for estimation of spatial genetic structure in tree populations. Heredity (Edinb); 2005 Oct;95(4):281-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To explore sampling limits, we created a model population with simulated distributions of dominant and codominant alleles, resulting from natural regeneration with restricted gene flow.
  • For both marker types, sampling ranges were evident, with lower limits below which estimation was poorly correlated and upper limits above which sampling became inefficient.
  • Lower limits (correlation of 0.9) were 100 individuals, 10 loci for microsatellites and 150 individuals, 100 loci for AFLPs.
  • Upper limits were 200 individuals, five loci for microsatellites and 200 individuals, 100 loci for AFLPs.
  • The limits indicated by simulation were compared with data sets from real species.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030529.001).
  • [ISSN] 0018-067X
  • [Journal-full-title] Heredity
  • [ISO-abbreviation] Heredity (Edinb)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


86. AbuTarif MA, Krishna G, Statkevich P: Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin; 2010 Feb;26(2):397-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These covariates included demographics, mucositis, neutropenia, vomiting, diarrhea, proton pump inhibitor (PPI) or H(2)-receptor antagonist usage and baseline bilirubin or baseline gamma-glutamyl transferase (GGT) levels > or =2 x upper limit of normal (ULN).
  • RESULTS: Statistically significant associations were demonstrated between posaconazole PK and diarrhea, PPI intake, race, and baseline GGT and bilirubin levels.


87. Gerstein J, Meyer A, Sykora KW, Frühauf J, Karstens JH, Bremer M: Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT). Strahlenther Onkol; 2009 Nov;185(11):751-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term renal toxicity in children following fractionated total-body irradiation (TBI) before allogeneic stem cell transplantation (SCT).
  • PURPOSE: To retrospectively assess the incidence and time course of renal dysfunction in children (< or = 16 years) following total- body irradiation (TBI) before allogeneic stem cell transplantation (SCT).
  • Renal dysfunction was defined as an increase of serum creatinine > 1.25 times the upper limit of age-dependent normal.
  • [MeSH-major] Dose Fractionation. Hematopoietic Stem Cell Transplantation. Kidney / radiation effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiation Injuries / etiology. Transplantation Conditioning. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 1998 Feb;174(2):92-104 [9487372.001]
  • [Cites] Strahlenther Onkol. 2007 Jul;183(7):385-91 [17609872.001]
  • [Cites] Strahlenther Onkol. 2006 Aug;182(8):443-9 [16896590.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 15;54(4):1165-73 [12419445.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):579-85 [8636774.001]
  • [Cites] Pediatr Nephrol. 2002 Dec;17 (12 ):1032-7 [12478353.001]
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):67-72 [18259697.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):6-7 [11197374.001]
  • [Cites] Strahlenther Onkol. 2008 Jul;184(7):376-80 [19016037.001]
  • [Cites] Strahlenther Onkol. 2006 Apr;182(4):222-30 [16622624.001]
  • [Cites] Radiother Oncol. 2001 Mar;58(3):227-33 [11230882.001]
  • [Cites] Bone Marrow Transplant. 2007 Jun;39(11):717-23 [17401393.001]
  • [Cites] Radiother Oncol. 2009 Feb;90(2):242-6 [18973960.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):661-2 [14967417.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):843-51 [8598361.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):545-51 [17896085.001]
  • [Cites] Strahlenther Onkol. 2005 Nov;181(11):704-8 [16254705.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):809-16 [14967438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1436-43 [18355974.001]
  • [Cites] Strahlenther Onkol. 2003 Oct;179(10):702-7 [14566479.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1228-32 [16682132.001]
  • [Cites] Bone Marrow Transplant. 1997 Dec;20(12):1069-74 [9466280.001]
  • [Cites] Bone Marrow Transplant. 2002 Jan;29(2):129-36 [11850707.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):289-95 [18535803.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):672-9 [17072526.001]
  • [Cites] Radiat Res. 1976 Oct;68(1):177-83 [967972.001]
  • [Cites] Strahlenther Onkol. 2008 May;184(5):276-80 [18427759.001]
  • (PMID = 19899009.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


88. Tanaka K: Genetic variation in flight activity of Ophraella communa (Coleoptera: Chrysomelidae): heritability estimated by artificial selection. Environ Entomol; 2009 Feb;38(1):266-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The O. communa population exhibited substantial variation in flight activity among individuals.
  • Repeatability of the following five flight components was analyzed: the total flight time, longest duration of single flight, mean duration of single flights, number of single flights, and a fly-or-not criterion (flying at least once [1] or nothing at all [0]) because it defines a theoretical upper limit of heritability.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19791623.001).
  • [ISSN] 0046-225X
  • [Journal-full-title] Environmental entomology
  • [ISO-abbreviation] Environ. Entomol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Tang F, Liu W: An age-dependent feedback control model of calcium dynamics in yeast cells. J Math Biol; 2010 Jun;60(6):849-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The functional decline of selected proteins or organelles leads to aging at the intracellular level.
  • Combining the model with our experimental lifespan data, we predict an upper-limit of cytosolic calcium tolerance for cell survival.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1999 Sep 1;18(17):4733-43 [10469652.001]
  • [Cites] J Biol Chem. 1990 Dec 5;265(34):21216-22 [2123488.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9895-901 [9092527.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11205-9 [7479966.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):319-25 [17517041.001]
  • [Cites] J Cell Biol. 2002 Jun 10;157(6):1017-28 [12058017.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2005 Jul;289(1):L2-4 [15955897.001]
  • [Cites] Front Biosci. 2000 May 01;5:D504-26 [10799358.001]
  • [Cites] Hum Mol Genet. 2000 Apr 12;9(7):1131-40 [10767338.001]
  • [Cites] J Theor Biol. 2008 Jun 21;252(4):608-20 [18374950.001]
  • [Cites] Biophys J. 1996 Mar;70(3):1198-213 [8785278.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):778-82 [15670846.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6686-94 [10958666.001]
  • [Cites] Exp Gerontol. 2006 Jan;41(1):11-24 [16307857.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38245-53 [10991947.001]
  • [Cites] EMBO J. 2002 May 15;21(10):2343-53 [12006487.001]
  • [Cites] Cell Calcium. 2006 Apr;39(4):337-48 [16445978.001]
  • [Cites] J Biol Chem. 1993 Jun 25;268(18):13267-73 [8390460.001]
  • [Cites] FEBS Lett. 1992 Aug 3;307(3):249-52 [1322832.001]
  • [Cites] Nature. 2003 Mar 6;422(6927):87-92 [12594460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7801-5 [11427713.001]
  • [Cites] Nature. 1993 Sep 23;365(6444):352-5 [8397339.001]
  • [Cites] Science. 2005 Nov 18;310(5751):1193-6 [16293764.001]
  • [Cites] Adv Appl Bioinform Chem. 2009;2:49-56 [21918615.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3730-41 [8668190.001]
  • [Cites] Nature. 1991 Aug 29;352(6338):803-7 [1715516.001]
  • [Cites] Biochemistry. 1999 Nov 2;38(44):14534-41 [10545175.001]
  • [Cites] J Cell Biol. 2002 Jan 7;156(1):29-34 [11781332.001]
  • [Cites] Cell Calcium. 2007 Aug;42(2):103-10 [17349691.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):608-19 [11877380.001]
  • [Cites] FEBS Lett. 1993 May 24;323(1-2):113-8 [8495722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7105-10 [12771382.001]
  • [Cites] Bull Math Biol. 2005 May;67(3):433-65 [15820737.001]
  • [Cites] Mol Microbiol. 2003 Jan;47(1):223-34 [12492866.001]
  • [Cites] J Biol Chem. 1983 May 10;258(9):5614-7 [6343390.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):297-305 [17517040.001]
  • [Cites] Curr Genet. 2004 Feb;45(2):83-9 [14618376.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2313-6 [11096121.001]
  • [Cites] J Theor Biol. 2000 Jan 21;202(2):145-60 [10640434.001]
  • [Cites] Science. 1991 Mar 1;251(4997):1076-8 [1825521.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7273-8 [8125940.001]
  • [Cites] Annu Rev Genet. 2001;35:647-72 [11700296.001]
  • [Cites] Circ Res. 2006 May 26;98 (10 ):1273-81 [16627785.001]
  • [Cites] Mol Cell Biol. 1996 May;16(5):2226-37 [8628289.001]
  • [Cites] Nature. 1994 Apr 28;368(6474):875-8 [8159248.001]
  • [Cites] EMBO J. 1998 Sep 15;17 (18):5298-308 [9736609.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6200-6 [11080502.001]
  • [Cites] J Physiol. 2003 Oct 15;552(Pt 2):333 [14561817.001]
  • [Cites] J Biochem. 2003 Jul;134(1):137-42 [12944380.001]
  • [Cites] Science. 1988 Jul 29;241(4865):589-91 [3041591.001]
  • [Cites] Biochemistry. 1993 Apr 6;32(13):3261-70 [8461293.001]
  • [Cites] J Cell Biol. 1994 Feb;124(3):351-63 [7507493.001]
  • [Cites] Biophys J. 1992 Mar;61(3):649-60 [1324019.001]
  • [Cites] Autophagy. 2008 Oct;4(7):874-86 [18690010.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jul;6(7):583-9 [16072039.001]
  • [Cites] Mol Biol Cell. 2000 Jan;11(1):369-91 [10637314.001]
  • [Cites] Mol Biol Cell. 2004 Aug;15(8):3841-62 [15169868.001]
  • [Cites] Mech Ageing Dev. 2005 Jan;126(1):17-21 [15610758.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45751-8 [12351653.001]
  • [Cites] J Cell Biol. 2009 May 18;185(4):601-12 [19433450.001]
  • [Cites] Biosci Biotechnol Biochem. 2007 Mar;71(3):633-45 [17341827.001]
  • [Cites] FEBS Lett. 1999 May 21;451(2):132-6 [10371152.001]
  • [Cites] Mol Gen Genet. 2000 Sep;264(1-2):29-36 [11016830.001]
  • [Cites] Cell Calcium. 1986 Feb;7(1):1-12 [2420465.001]
  • [Cites] J Theor Biol. 2004 Jul 21;229(2):189-96 [15207474.001]
  • [Cites] Cell Signal. 1990;2(5):497-507 [2177621.001]
  • [Cites] Eur J Pharmacol. 2005 Feb 10;509(1):21-30 [15713425.001]
  • [Cites] J Cell Biol. 2004 Jan 19;164(2):195-206 [14734531.001]
  • [Cites] J Cell Sci. 2003 Apr 15;116(Pt 8):1637-46 [12640047.001]
  • [Cites] J Mol Biol. 2003 Mar 14;327(1):31-45 [12614606.001]
  • [Cites] Aging Cell. 2007 Jun;6(3):307-17 [17465978.001]
  • [Cites] PLoS Biol. 2004 Sep;2(9):E296 [15328540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3254-9 [10716729.001]
  • [Cites] Cell Calcium. 2009 Feb;45(2):123-32 [18783827.001]
  • [Cites] Nat Biotechnol. 2007 Sep;25(9):1001-6 [17846631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9100-5 [10430902.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5939-47 [10026219.001]
  • [Cites] Methods. 2007 Feb;41(2):238-47 [17189866.001]
  • [Cites] J Bacteriol. 1993 May;175(10):2853-8 [8491706.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):10113-9 [7537264.001]
  • [Cites] J Cell Biol. 2004 Jan 5;164(1):35-46 [14699087.001]
  • [Cites] Bioessays. 1999 Jan;21(1):38-46 [10070252.001]
  • (PMID = 19672599.001).
  • [ISSN] 1432-1416
  • [Journal-full-title] Journal of mathematical biology
  • [ISO-abbreviation] J Math Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Molecular Chaperones; 0 / Saccharomyces cerevisiae Proteins; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / PMC1 protein, S cerevisiae; EC 3.6.3.8 / Plasma Membrane Calcium-Transporting ATPases; EC 3.6.3.8 / SSC1 protein, S cerevisiae; SY7Q814VUP / Calcium
  •  go-up   go-down


90. Vincent E, Gu Z, Morgenstern M, Gibson C, Pan J, Hayden RT: Detection of cytomegalovirus in whole blood using three different real-time PCR chemistries. J Mol Diagn; 2009 Jan;11(1):54-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The samples included 149 clinical whole blood specimens that were de-identified and assayed in parallel with all primer-probe systems.
  • Quantitative linearity reached an upper limit of 10(5) copies per reaction for all methods.
  • [MeSH-major] Cytomegalovirus / isolation & purification. Cytomegalovirus Infections / diagnosis. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1723-7 [17409210.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):4237-41 [17005757.001]
  • [Cites] J Clin Microbiol. 2008 Jan;46(1):157-63 [17989187.001]
  • [Cites] J Clin Virol. 2008 Mar;41(3):237-41 [18203657.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2536-42 [10878039.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2734-7 [10878073.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1987-9 [11106331.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):772-5 [11158149.001]
  • [Cites] J Virol Methods. 2001 Apr;93(1-2):105-13 [11311349.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4362-9 [11724846.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4472-6 [11724864.001]
  • [Cites] J Virol Methods. 2002 Mar;101(1-2):149-57 [11849693.001]
  • [Cites] Nucleic Acids Res. 2002 Mar 15;30(6):1292-305 [11884626.001]
  • [Cites] Transplantation. 2002 Mar 27;73(6):968-73 [11923702.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):831-40 [12153173.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3167-74 [12843059.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4636-41 [14532195.001]
  • [Cites] J Am Chem Soc. 2004 Apr 14;126(14):4550-6 [15070373.001]
  • [Cites] J Clin Virol. 2004 Jul;30(3):258-66 [15135746.001]
  • [Cites] J Clin Virol. 2004 Dec;31(4):239-47 [15494263.001]
  • [Cites] PCR Methods Appl. 1995 Jun;4(6):357-62 [7580930.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10756-61 [9380706.001]
  • [Cites] Clin Chem. 1998 Jan;44(1):12-26 [9550553.001]
  • [Cites] Herpes. 2004 Dec;11(3):77-86 [15960905.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1132-6 [15976098.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Aug;49(8):3334-40 [16048944.001]
  • [Cites] Transplant Proc. 2005 Nov;37(9):4094-6 [16386635.001]
  • [Cites] J Mol Diagn. 2006 Feb;8(1):89-96 [16436639.001]
  • [Cites] J Clin Microbiol. 2007 Jul;45(7):2151-5 [17494720.001]
  • (PMID = 19074593.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Indicators and Reagents
  • [Other-IDs] NLM/ PMC2607566
  •  go-up   go-down


91. Izuwa Y, Ueshima S, Sato T, Okazaki M, Aiba T, Kawasaki H, Kurosaki Y, Sendo T: [Frequency of decreased renal function between patients treated with brand and generic products of vancomycin hydrochloride injection]. Yakugaku Zasshi; 2008 Oct;128(10):1493-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The renal function of those patients was evaluated based on the serum creatinine concentration (SCr), and patients whose SCr was maximally elevated above the defined upper limit of the normal range (1.20 mg/dl for males and 0.96 mg/dl for females) were considered to show decreased renal function.
  • It was additionally revealed that 3 of those 4 patients with a decreased renal function related to the generic product were not treated as instructed by the package insert, and their trough VCM concentration exceeded the recommended level of 10 microg/ml.
  • [MeSH-major] Anti-Bacterial Agents / adverse effects. Drugs, Generic. Kidney Diseases / chemically induced. Kidney Diseases / epidemiology. Vancomycin / adverse effects

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827470.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Biomarkers; 0 / Drugs, Generic; 6Q205EH1VU / Vancomycin; AYI8EX34EU / Creatinine
  •  go-up   go-down


92. Istomin AY, Jacobs DJ, Livesay DR: On the role of structural class of a protein with two-state folding kinetics in determining correlations between its size, topology, and folding rate. Protein Sci; 2007 Nov;16(11):2564-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, the sets of data points for the all-alpha and all-beta classes define asymptotes of lower and upper limits on folding rates of mixed-class proteins.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biopolymers. 1983 Dec;22(12):2577-637 [6667333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8942-4 [15184682.001]
  • [Cites] Fold Des. 1998;3(4):R81-91 [9710577.001]
  • [Cites] Biophys Chem. 2005 Jan 1;113(1):9-16 [15617806.001]
  • [Cites] J Am Chem Soc. 2005 Jan 19;127(2):480-1 [15643845.001]
  • [Cites] Protein Sci. 2005 Mar;14(3):602-16 [15689503.001]
  • [Cites] Proteins. 2006 Apr 1;63(1):144-54 [16400647.001]
  • [Cites] Biochemistry. 2006 Mar 21;45(11):3805-12 [16533064.001]
  • [Cites] Proteins. 2007 Apr 1;67(1):12-7 [17206660.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14258-63 [10588693.001]
  • [Cites] J Mol Biol. 2000 Mar 31;297(3):791-802 [10731429.001]
  • [Cites] Biochemistry. 2000 Sep 19;39(37):11177-83 [10985762.001]
  • [Cites] Curr Opin Struct Biol. 2001 Feb;11(1):70-82 [11179895.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:361-96 [11340064.001]
  • [Cites] J Mol Biol. 2001 Jun 29;310(1):27-32 [11419934.001]
  • [Cites] Biophys J. 2002 Jan;82(1 Pt 1):458-63 [11751332.001]
  • [Cites] Protein Sci. 2003 Jan;12(1):17-26 [12493824.001]
  • [Cites] Proteins. 2003 May 1;51(2):162-6 [12660985.001]
  • [Cites] J Mol Biol. 2003 Apr 11;327(5):1149-54 [12662937.001]
  • [Cites] Protein Sci. 2003 Sep;12(9):2057-62 [12931003.001]
  • [Cites] J Chem Inf Comput Sci. 2003 Sep-Oct;43(5):1481-5 [14502481.001]
  • [Cites] Proteins. 2004 Feb 1;54(2):333-41 [14696195.001]
  • [Cites] J Mol Biol. 1998 Apr 10;277(4):985-94 [9545386.001]
  • (PMID = 17962408.001).
  • [ISSN] 0961-8368
  • [Journal-full-title] Protein science : a publication of the Protein Society
  • [ISO-abbreviation] Protein Sci.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM073082; United States / NIGMS NIH HHS / GM / R01 GM073082-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins
  • [Other-IDs] NLM/ PMC2211710
  •  go-up   go-down


93. Schell H, Epari DR, Kassi JP, Bragulla H, Bail HJ, Duda GN: The course of bone healing is influenced by the initial shear fixation stability. J Orthop Res; 2005 Sep;23(5):1022-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An upper limit of stability required for successful healing remains unknown, however a limit by which healing is less optimal has been determined.
  • [MeSH-minor] Animals. Biomechanical Phenomena. Bony Callus / pathology. External Fixators. Female. Osteotomy. Sheep. Tibia / pathology. Tibia / physiopathology. Tibia / radiography. Tibial Fractures / physiopathology. Tibial Fractures / surgery. Time Factors. Torsion Abnormality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878254.001).
  • [ISSN] 0736-0266
  • [Journal-full-title] Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  • [ISO-abbreviation] J. Orthop. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


94. Held RT, Zderic V, Nguyen TN, Vaezy S: Annular phased-array high-intensity focused ultrasound device for image-guided therapy of uterine fibroids. IEEE Trans Ultrason Ferroelectr Freq Control; 2006 Feb;53(2):335-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annular phased-array high-intensity focused ultrasound device for image-guided therapy of uterine fibroids.
  • An ultrasound (US), image-guided high-intensity focused ultrasound (HIFU) device was developed for noninvasive ablation of uterine fibroids.
  • The variation in lesion dimensions indicates the possible development of HIFU protocols that increase HIFU throughput and shorten tumor treatment times.
  • [MeSH-major] Image Interpretation, Computer-Assisted / instrumentation. Leiomyoma / therapy. Leiomyoma / ultrasonography. Therapy, Computer-Assisted / instrumentation. Ultrasonic Therapy / instrumentation. Ultrasonography / instrumentation. User-Computer Interface

  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529108.001).
  • [ISSN] 0885-3010
  • [Journal-full-title] IEEE transactions on ultrasonics, ferroelectrics, and frequency control
  • [ISO-abbreviation] IEEE Trans Ultrason Ferroelectr Freq Control
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


95. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, McGregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M: Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend; 2007 Dec 1;91(2-3):228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HCV incidence was estimated to be 9700 (lower and upper limits of 6600 and 13,200) in 2005.
  • An estimated 264,000 (lower and upper limits of 206,000 and 318,000) people were HCV antibody positive in 2005.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17669601.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


96. Cibula D, Karck U, Weidenhammer HG, Kunz J, Alincic S, Marr J: Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20microg and drospirenone 3mg. Clin Drug Investig; 2006;26(3):143-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This was an open-label, non-comparative, multicentre study conducted at 33 centres in Germany and Switzerland.
  • Two pregnancies occurred during 11 165 cycles of treatment, giving a Pearl Index of 0.23 (upper limit of 97.5% CI 0.84).
  • The corresponding 2-year cumulative pregnancy rate was 0.44% (95% CIs 0, 1.05).
  • One of the two pregnancies was attributed to non-compliance with treatment, giving an adjusted Pearl Index of 0.12 (upper limit of 97.5% CI 0.67) over 10 827 compliant cycles.

  • Hazardous Substances Data Bank. ETHINYLESTRADIOL .
  • Hazardous Substances Data Bank. Drospirenone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Contracept Reprod Health Care. 2000 Jun;5(2):124-34 [10943575.001]
  • [Cites] Contraception. 1999 Nov;60(5):269-74 [10717778.001]
  • [Cites] Contraception. 1997 Mar;55(3):139-44 [9115001.001]
  • [Cites] Contraception. 1995 Oct;52(4):229-35 [8605781.001]
  • [Cites] Eur J Contracept Reprod Health Care. 2000 Mar;5(1):25-34 [10836660.001]
  • [Cites] Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 3:13-8; discussion 42-3 [12659402.001]
  • [Cites] Gynecol Endocrinol. 1996 Feb;10(1):33-9 [8737190.001]
  • [Cites] Cutis. 2002 Apr;69(4 Suppl):2-15 [12096825.001]
  • [Cites] Contraception. 2003 Aug;68(2):89-96 [12954519.001]
  • [Cites] Cutis. 2004 Aug;74(2):123-30 [15379365.001]
  • [Cites] J Reprod Med. 1995 May;40(5):355-60 [7608875.001]
  • [Cites] Contraception. 1996 Oct;54(4):243-51 [8922878.001]
  • [Cites] Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):577-82 [9757954.001]
  • [Cites] Contraception. 2000 Feb;61(2):105-11 [10802275.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jul;179(1):S2-8 [9704812.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Sep;100(9):832-8 [8218004.001]
  • [Cites] Eur J Contracept Reprod Health Care. 2003 Jun;8(2):87-92 [12836662.001]
  • [Cites] Contraception. 2001 Sep;64(3):201-7 [11704101.001]
  • [Cites] Contraception. 1997 Mar;55(3):131-7 [9115000.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Apr;86(4):325-9 [373792.001]
  • [Cites] Contraception. 1995 Feb;51(2):99-110 [7750297.001]
  • [Cites] Am J Obstet Gynecol. 1999 Nov;181(5 Pt 2):39-44 [10561674.001]
  • (PMID = 17163245.001).
  • [ISSN] 1173-2563
  • [Journal-full-title] Clinical drug investigation
  • [ISO-abbreviation] Clin Drug Investig
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Androstenes; 0 / Contraceptives, Oral, Combined; 423D2T571U / Ethinyl Estradiol; N295J34A25 / drospirenone
  •  go-up   go-down


97. Tripathi M, Khurana A, D'Souza MM, Sharma R: Pitfall of (18)F-FDG-PET imaging in oncology: uterine fibromyoma. Hell J Nucl Med; 2009 May-Aug;12(2):175-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pitfall of (18)F-FDG-PET imaging in oncology: uterine fibromyoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Leiomyoma / radionuclide imaging. Positron-Emission Tomography / methods. Uterine Neoplasms / radionuclide imaging
  • [MeSH-minor] False Negative Reactions. Female. Humans. Medical Oncology / methods. Middle Aged. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19675878.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Mayr D, Straub J, Müller-Höcker J: [Schistosomiasis in a leiomyoma of the uterus]. Pathologe; 2005 Jul;26(4):300-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Schistosomiasis in a leiomyoma of the uterus].
  • [Transliterated title] Schistosomiasis in einem uterinen Leiomyom.
  • This case report deals with an, in our regions, unusual diagnosis of coincidence of a genital schistosomiasis of a 30-year-old woman, coming from Africa.
  • After clinical examination the patient underwent an operation because of an uterus myomatosus.
  • After pathological diagnosis the patient underwent the standard therapy with a single injection of praziquantel.
  • [MeSH-major] Leiomyoma / pathology. Schistosomiasis mansoni / pathology. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trop Med Int Health. 2003 Jun;8(6):561-8 [12791062.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):491-2 [11906555.001]
  • [Cites] Acta Trop. 2003 May;86(2-3):309-13 [12745147.001]
  • [Cites] N Engl J Med. 2002 Apr 18;346(16):1212-20 [11961151.001]
  • [Cites] Afr Health Sci. 2002 Dec;2(3):99-106 [12789093.001]
  • [Cites] Parasitol Res. 2003 Jun;90 Supp 1:S3-9 [12811543.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):211-4 [12821368.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 May 1;108(1):106-8 [12694982.001]
  • [Cites] Acta Trop. 2000 Nov 2;77(2):179-83 [11080508.001]
  • [Cites] Trop Med Int Health. 2000 Mar;5(3):185-91 [10747281.001]
  • [Cites] J Infect Dis. 2000 Mar;181(3):1210-3 [10720558.001]
  • [Cites] Acta Trop. 2001 Jun 22;79(3):193-210 [11412803.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2002;97 Suppl 1:167-9 [12426614.001]
  • [Cites] World Health Organ Tech Rep Ser. 2002;912:i-vi, 1-57, back cover [12592987.001]
  • (PMID = 15490172.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Chong KM, Chuang J, Tsai YL, Hwang JL: A rapidly growing paraurethral myoma with profuse bleeding from a mucosal vessel: report of a case. Gynecol Obstet Invest; 2006;61(2):87-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapidly growing paraurethral myoma with profuse bleeding from a mucosal vessel: report of a case.
  • Paraurethral leiomyoma is rare.
  • This is the first reported case of a woman with a 6 x 7 x 5 cm urethral leiomyoma with profuse vaginal bleeding.
  • Profuse bleeding from a paraurethral myoma is possibly due to increased vascularity and the prolapsed nature of the tumor in this area.
  • [MeSH-major] Leiomyoma / complications. Leiomyoma / diagnosis. Uterine Hemorrhage / etiology. Vaginal Neoplasms / complications. Vaginal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16244489.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Ahmed HU, Arya M, Muneer A, Mushtaq I, Sebire NJ: Testicular and paratesticular tumours in the prepubertal population. Lancet Oncol; 2010 May;11(5):476-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumours within this group are testicular germ-cell tumours (such as benign teratoma, epidermoid cyst and malignant yolk-sac tumours) and stromal tumours (such as juvenile granulosa-cell, Leydig-cell, and Sertoli-cell tumours).
  • Paratesticular tumours can be benign (lipoma, leiomyoma, haemangioma) or malignant (rhabdomyosarcoma, melanotic neuroectodermal tumour of infancy).
  • [MeSH-major] Genital Neoplasms, Male / diagnosis. Genital Neoplasms, Male / therapy
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / therapy. Sex Cord-Gonadal Stromal Tumors / diagnosis. Sex Cord-Gonadal Stromal Tumors / epidemiology. Sex Cord-Gonadal Stromal Tumors / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / epidemiology. Testicular Neoplasms / therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • [CommentIn] Lancet Oncol. 2010 Sep;11(9):814 [20816371.001]
  • (PMID = 20434716.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0701302; United Kingdom / Medical Research Council / / G1002509
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down






Advertisement